document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information item c disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead science ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig report refer trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue forecast variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forwardlooke statement include statement overall trend operate cost revenue trend liquidity capital need plan expectation respect product product candidate corporate strategy business operation financial projection use capital collaboration licensing arrangement ongoing litigation investigation matter statement anticipate future impact business ongoing coronavirus disease covid relate public health measure statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify item annual report head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof specify require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption evaluate business carefully consider risk describe section entitle risk factor item annual report risk contain materially adversely affect business result operation financial condition item business gilead sciences inc gilead biopharmaceutical company pursue achieve breakthrough medicine decade goal create healthy world people commit advance innovative medicine prevent treat lifethreatening disease include hiv viral hepatitis cancer operate country worldwide headquarters foster city california business product innovative medicine represent advancement offer firstinclass treatment great efficacy enhance mode delivery convenient treatment regimen improve resistance profile reduce effect focus innovation allow deliver market product multiple therapeutic area primary revenuegenerating product approve indication united states follow hivaids biktarvy oral formulation dose day treatment hiv infection certain patient biktarvy singletablet regiman fixeddose combination antiretroviral medication bictegravir emtricitabine tenofovir alafenamide taf genvoya oral formulation dose day treatment hiv infection certain patient genvoya singletablet regiman fixeddose combination antiretroviral medicine elvitegravir cobicistat emtricitabine taf descovy oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient descovy fixeddose combination antiretroviral medication emtricitabine taf descovy approve food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquire hiv infection certain atrisk patient odefsey oral formulation dose day treatment hiv infection certain patient odefsey singletablet regiman fixeddose combination antiretroviral medication emtricitabine taf rilpivirine market janssen sciences ireland unlimited company janssen pharmaceutical companies johnson johnson janssen truvada oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient truvada fixeddose combination antiretroviral medication tenofovir disoproxil fumarate tdf emtricitabine truvada approve fda prep indication reduce risk sexually acquire hiv infection certain atrisk patient compleraeviplera oral formulation dose day treatment hiv infection certain patient product market united states complera europe eviplera singletablet regiman fixeddose combination antiretroviral medication tdf emtricitabine janssen rilpivirine hydrochloride stribild oral formulation dose day treatment hiv infection certain patient stribild singletablet regiman fixeddose combination antiretroviral medication elvitegravir cobicistat tdf emtricitabine atripla oral formulation indicate complete regimen treatment hiv infection certain patient atripla fixeddose combination antiretroviral medication tdf emtricitabine bristolmyers squibb company bmss efavirenz covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicate treatment coronavirus disease covid certain adult child year age old weighing pound kg hospitalize ii hospitalize mildtomoderate covid high risk progression severe covid include hospitalization death indication receive expedite approval fda january liver disease epclusa oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adult certain pediatric patient genotype cirrhosis compensate cirrhosis ii decompensate cirrhosis use combination ribavirin addition authorize generic version epclusa distribute separate subsidiary asegua therapeutics llc harvoni oral formulation oncedaily singletablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii adult genotype decompensate cirrhosis combination ribavirin iii adult genotype liver transplant recipient cirrhosis compensate cirrhosis combination ribavirin iv certain pediatric patient genotype cirrhosis compensate cirrhosis addition authorize generic version harvoni distribute separate subsidiary asegua therapeutics llc vosevi oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adult genotype previously treat nsa inhibitorcontaine regimen ii genotype previously treat sofosbuvircontaine regimen nsa inhibitor vemlidy oral formulation taf dose day treatment chronic hepatitis b virus hbv infection adult compensate liver disease viread oral formulation tdf dose day treatment chronic hbv infection adult certain pediatric patient hematologyoncologycell therapy yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car tcell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma dlbcl specify primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arise follicular lymphoma ii adult patient relapse refractory follicular lymphoma fl line systemic therapy indication approve accelerate approval fda continue approval indication contingent verification description clinical benefit confirmatory trial tecartus brexucabtagene autoleucel suspension intravenous infusion car cell therapy treatment adult patient relapse refractory mantle cell lymphoma mcl ii adult patient relapse refractory bcell precursor acute lymphoblastic leukemia trodelvy sacituzumab govitecanhziy injection intravenous use trop direct antibody topoisomerase inhibitor conjugate indicate treatment adult patient unresectable locally advanced metastatic triplenegative breast cancer tnbc receive prior systemic therapy metastatic disease ii adult patient locally advanced metastatic urothelial cancer previously receive platinumcontaine chemotherapy program death receptor pd program deathligand pdl inhibitor indication approve accelerate approval fda continue approval indication contingent verification description clinical benefit confirmatory trial zydelig idelalisib oral formulation kinase inhibitor treatment patient relapse chronic lymphocytic leukemia combination rituximab rituximab consider appropriate therapy comorbiditie letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsen ii combination tadalafil reduce risk disease progression hospitalization worsen pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment invasive fungal infection cause fungal specie adult information revenuegenerate product include revenue contribute product list note revenue note consolidated financial statement include ii item annual report revenue share revenue generate revenue activity include revenue share combination product royaltie outbound license intellectual property payment receive collaboration thirdparty partner example pursuant collaboration janssen receive revenue share cobicistat emtricitabine taf components symtuza darunavircobicistatemtricitabinetaf fixeddose combination product commercialize janssen include revenue share symtuza product sale description collaboration janssen partner note collaboration arrangement note consolidated financial statement include ii item annual report form k commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute product united states exclusively wholesale channel year end december approximately product sale united states approximately total worldwide revenue large wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute product europe country outside united states product approve commercial team thirdparty distributor corporate partner competition operate highly competitive environment face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete commercially available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature pricing pressure private insurer government payer result reduction net product price new brand generic product introduce major market ability maintain pricing market share affect research development research development rd mission discover develop transformational therapy area high unmet medical need product development effort focus primarily viral disease inflammatory disease oncology team research scientist engage discovery development new molecule technology hope lead approval innovative medicine therapy advance current standard care address unmet medical need intend continue commit significant resource internal rd opportunity external business development activity drive innovation growth business development product candidate investigational therapy pipeline subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial include account clinical hold place regulatory authority perform additional trial risk fail obtain regulatory approval result product candidate investigational therapy successfully commercialize drug development inherently risky product candidate investigational therapy fail development process continue invest advance rd pipeline therapeutic area summary product candidate phase registrational phase clinical trial pende marketing authorization review fda european medicines agency ema end product candidate viral disease product candidate description regulatory filing lenacapavir new drug application marketing authorization application file fda ema respectively lenacapavir hiv capsid inhibitor component longacte regimen treatment hiv infection heavily treatmentexperience people live hiv grant breakthrough therapy designation fda indication bulevirtide biologic license application file fda bulevirtide treatment chronic hepatitis delta virus hdv infection grant orphan drug breakthrough therapy designation fda indication europe hepcludex bulevirtide grant conditional marketing authorization european commission priority medicine prime scheme eligibility ema approve treatment adult chronic hdv infection compensate liver disease phase lenacapavir lenacapavir evaluate hiv prep indication program timeline pende resolution clinical hold place fda study evaluate injectable lenacapavir product candidate inflammatory disease product candidate description phase cilofexor cilofexor fxr agonist evaluate treatment primary sclerose cholangitis filgotinib filgotinib jak inhibitor evaluate treatment crohns disease product candidate oncology product candidate description regulatory filing yescarta axicabtagene ciloleucel supplemental biologics license application type ii variation marketing authorization application file fda ema respectively axicabtagene ciloleucel car cell therapy treatment secondline dlbcl type ii variation marketing authorization application file ema axicabtagene ciloleucel treatment relapse refractory fl yescarta receive accelerate approval fda treatment adult patient relapse refractory fl line systemic therapy tecartus brexucabtagene autoleucel type ii variation marketing authorization application file ema brexucabtagene autoleucel car cell therapy treatment adult tecartus receive fda approval treatment adult patient relapse refractory bcell precursor phase sacituzumab govitecanhziy sacituzumab govitecanhziy trop direct antibody topoisomerase inhibitor conjugate evaluate hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer ii nonsmall cell lung cancer nsclc secondline thirdline treatment magrolimab magrolimab anticd evaluate high risk myelodysplastic syndrome mds firstline treatment ii acute myeloid leukemia aml firstline treatment program timeline pende resolution partial clinical hold place fda study evaluate magrolimab zimberelimab zimberelimab antipd monoclonal antibody evaluate nsclc firstline treatment domvanalimab domvanalimab fcsilent antitigit antibody evaluate nsclc firstline treatment registrational phase brexucabtagene autoleucel brexucabtagene autoleucel evaluate treatment pediatric collaboration arcus biosciences inc arcus note collaboration arrangement note consolidated financial statement include ii item annual report additional information collaboration receive regulatory approval authorization fda european commission expand indication product include product regulatory approval authorization biktarvy fda approve new lowdose tablet dosage form biktarvy pediatric patient weigh kg kg virologically suppress new antiretroviral therapy epclusa fda approve expansion pediatric indication epclusa treatment chronic hcv infection include pediatric patient year age old regardless hcv genotype liver disease severity veklury european commission approve variation conditional marketing authorization veklury include adult require supplemental oxygen increase risk progress severe covid yescarta fda grant accelerated approval yescarta treatment adult patient relapse refractory fl tecartus fda approve tecartus treatment adult patient relapse refractory bcell precursor trodelvy fda grant approval trodelvy adult patient unresectable locally advanced metastatic tnbc fda grant accelerated approval trodelvy use adult patient locally advanced metastatic uc european commission grant marketing authorization trodelvy monotherapy indicate treatment adult patient unresectable metastatic tnbc receive prior systemic therapy advanced disease addition seek enhance commercial portfolio clinical pipeline multiple therapeutic area acquisition inlicense strategic collaboration example october enter clinical trial collaboration merck sharp dohme corp subsidiary merck co inc merck evaluate trodelvy combination merck keytruda patient firstline metastatic tnbc november expand research collaboration arcus exercise option program arcuss clinicalstage portfolio include domvanalimab phase study nsclc strategic business development activity reflect commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent key product candidate describe product candidate fixeddose combination singletablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient singletablet regiman key product candidate patent expiration eu viral disease lenacapavir bulevirtide inflammatory disease cilofexor filgotinib oncology axicabtagene ciloleucel brexucabtagene autoleucel sacituzumab govitecanhziy magrolimab zimberelimab domvanalimab composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite gilead company kite application patent term extension file united states grant extend expiration date regulatory exclusivity united states expire collaboration arcus follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent principal product product fixeddose combination singletablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient singletablet regimen product patent expiration eu ranexa descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy jyseleca hepcludex estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead lupin limit reach agreement settle patent litigation matter relate ranexa application patent term extension pende united states andor spc pende country european union product composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite gilead mylan pharmaceutical reach agreement settle patent litigation concern patent protect cobicistat stribild genvoya product application patent term extension file united states grant extend expiration date regulatory exclusivity united states expire patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api hiv product cell therapy product hold party acquire exclusive right patent agreement party obtain patent certain product year marketing approval obtain patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party reputation harm require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel brexucabtagene autoleucel tenofovir disoproxil tenofovir alafenamide bictegravir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation postgrant proceeding patent trademark office proceeding determine right patent validity patent grant litigation proceeding unpredictable expensive divert management attention operation ultimately successful adversely impact patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country provide effective enforcement patent thirdparty manufacturer able sell generic version product country description significant pende legal proceeding note commitment contingency note consolidated financial statement include ii item annual report item risk factor success depend significant degree ability obtain defend patent intellectual property right domestically internationally operate infringe patent proprietary right party trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material product manufacture facility thirdparty contract manufacturer depend party perform manufacturing activity majority api drug product product include hiv hcv product use multiple thirdparty contract manufacturer primary backup supplier manufacturing site cell therapy product establish clinical commercial manufacturing facility cell processing activity future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility lease manufacturing facility manufacture distribute certain product api clinical andor commercial use facility include foster city california conduct process chemistry research formulation development activity manufacture api drug product clinical trial oversee thirdparty contract manufacturer san dimas la verne california manufacture ambisome package label majority commercial product distribution america pacific rim oceanside california utilize facility clinical manufacturing process development biologic candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy product frederick maryland utilize facility clinical manufacturing processing cell therapy product morris plain new jersey utilize facility manufacturing monoclonal antibody intermediate process optimization antibody drug conjugate product cork dublin ireland utilize cork facility commercial manufacturing packaging labeling product perform quality control testing labeling package final release product cork facility distribute european union international market facility dublin utilize facility central dublin drug development hub pediatric program perform clinical development safety quality biostatistic datum science regulatory compliance function edmonton canada conduct process chemistry research scaleup activity clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process hoofddorp netherland utilize facility commercial manufacturing processing cell therapy product thirdparty manufacturer believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict reveal technology certain thirdparty manufacturer comply restriction information thirdparty manufacturer item risk factor face manufacture difficulty delay interruption include thirdparty manufacturer corporate partner regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility observe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect jurisdiction manufacture operation subject routine inspection regulatory agency cell therapy product require fda comply risk evaluation mitigation strategy program include educate certify medical personnel therapy procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient access raw material need access certain raw material conduct clinical trial manufacture product raw material generally available multiple source purchase worldwide normally available quantity adequate meet need business attempt manage risk associate supply chain inventory management relationship management evaluation alternative source feasible information item risk factor able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue human capital gilead success depend work dedicated employee embrace share sense purpose culture excellence human capital objective gilead employer choice good talent industry gilead key priority human capital management include inclusion diversity health safety total reward employee development engagement compensation talent committee board director oversee overall human capital management inclusion diversity inclusion gilead core value believe building inclusive diverse workforce critical enable gilead mission global inclusion diversity council responsible governance matter track progress goal promote culture inclusion global inclusion diversity council chair chairman chief executive officer include member leadership team introduce advance black leadership strategy multiyear initiative outline commitment create internal external pipeline diverse talent build awareness capability accountability people manager strategy set clear target representation overall workforce executive population include goal increase percentage female black hispanic employee welldefine annual target gilead implement multiple program train manager inclusion diversity topic create strategy initiative focus attract develop retain diverse talent drive inclusive culture workplace organizational leader require regularly review start addition employee resource group erg support diverse employee aim raise awareness different culture workplace cultivate diversity business strength support gilead talent acquisition strategy source attract recruit diverse candidate executive sponsor leader ergs contribute advancement inclusion diversity commitment service global inclusion diversity council believe gilead inclusive diverse workforce foundation innovation productivity gilead commitment equal employment opportunity further effort cultivate celebrate equitable culture belong december gilead approximately employee gilead global workforce approximately female male additionally woman represent gilead leadership define vice president level united states base employee voluntary selfidentification workforce white asian hispanic black health safety gilead commit provide workplace employee promote health safety wellness productivity workplace safety training security program compliance protocol support commitment routinely train educate employee workplace safety security response covid pandemic gilead site require flexible location employee work home employee need physically present position laboratory technician continue work gilead site fourth quarter gilead transition return tosite phase flexible location employee pandemic implement job site enhancement risk protocol include health screening covid testing vaccine requirement reconfiguration work common space allow physical distancing effort support safe occupancy site gilead maintain robust contact trace notification process employee report covid infection continue monitor state pandemic remain committed maintain work environment promote health safety productivity workforce total reward gilead compensation benefit program design help attract develop retain industry talented workforce total reward program vary country include competitive base salary incentive compensation stock award employee stock purchase plan k saving plan company match vest immediately health welfare valuable benefit flexible work arrangement flexible spending account pay time family leave family care resource fertility adoption surrogacy assistance student loan repayment tuition assistance employee assistance program global wellbeing reimbursement tuition assistance year reassess total reward package confirm offer benefit incentive align total reward philosophy payforperformance company commit address pay equity employee salary inform marketbase range assess annually performance career development review policy compensation decision regard personal characteristic gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status conduct annual pay equity review employee compensation effort strive pay practice gender race neutral employee development engagement employee development engagement maximize potential performance member workforce critical achieve business goal gilead offer number internal external professional management leadership development training program help employee develop technical crossfunctional leadership skill tool grow career addition employee receive reimbursement tuition expense incur pursue undergraduate graduate certificate course accredit college university strive employer choice industry listening strategy gather input employee shape engagement strategy program measure progress addition ongoing internal external data collection conduct largescale review employee experience employee survey result survey play key role determine direction culture company broad response continue covid pandemic include meaningful benefit provide employee approach flexible work arrangement believe flexible work program position competitive talent support employee wellbeing create collaborative environment connection fuel innovation environmental social governance esg invest corporate responsibility core business strategy reflect value accountability inclusion teamwork excellence integrity service mission advance global health provide innovative therapeutic area unmet need way socially responsible environmentally sustainable gilead esg program reflect commitment stakeholder esg strategy performance oversee nominate corporate governance committee board director manage corporate responsibility committee comprise leader key department company corporate responsibility committee responsible reviewing material esg issue integrate overall business strategy operation additional information program esg highlight available gileads year review gilead website wwwgileadcomnewsandpressannualreportyearinreview esg goal aspirational change statement goal relate initiative guarantee promise meet seasonality operation worldwide product sale reflect significant degree seasonality endus demand united states fluctuation wholesaler inventory level impact product sale typically observe strong wholesaler subwholesaler purchase product fourth quarter result inventory drawdown wholesaler subwholesaler subsequent quarter factor include government budget annual grant cycle federal state fund covid pandemic buying pattern impact product sale record particular quarter information item risk factor face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory government regulation operation activity subject extensive regulation numerous government authority united states european union country include law regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume significant impact capital expenditure result operation regulatory requirement applicable drug development approval subject change legal regulatory change impact operation future country regulatory agency fda united states ema european commission european union national authority european union member state approve drug sell respective country country general process drug approval united states summarize country include country european union european union centralize procedure similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer risk indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat prevent disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial phase drug candidate appear effective appropriate safety profile phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form new drug application biologic license application supplemental application fda seek approval sell drug candidate particular use fdas discretion fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree drug meet require level safety efficacy particular use approve application allow sell drug united states use unusual fda decline approve application believe drug candidate safe efficacious ie appropriate benefitrisk profile believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit manufacturing issue certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit approve drug fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard concern safety efficacy uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california license state california compliance local regulatory requirement manufacture facilities canada ireland netherlands obtain local license permit compliance local regulatory requirement fda employ tool facilitate expedite development review drug include fast track designation breakthrough therapy designation accelerate approval priority review designation fast track designation design facilitate development review drug treat condition fill unmet medical need breakthrough therapy designation design expedite development review drug treat condition preliminary clinical evidence demonstrate substantial improvement available therapy accelerate approval drug grant fda drug treat condition fill unmet medical need study safety efficacy priority review designation mean fda goal action application month file fda grant priority review designation drug provide significant improvement safety effectiveness treatment diagnosis prevention condition european union regulatory system approval process european union eu products subject variety eu eu member state regulation govern clinical trial commercial sale distribution require obtain marketing authorization eu market medicinal product relevant market conduct clinical trial eu govern directive ec directive ec eu ich good clinical practice rule impose legal regulatory obligation similar provide applicable law conduct clinical trial eu approve competent authority eu member states clinical trial place positive opinion obtain relevant ethic committee relevant member state eu legislator adopt regulation eu replace directive ec introduce coordinated procedure authorization clinical trial regulation enter application january marketing authorization holder manufacturer importer wholesaler distributor medicinal product place market eu require comply number regulatory requirement include pharmacovigilance gmp compliance requirement obtain manufacture import andor distribution license issue competent authority eu member states failure comply requirement lead imposition civil criminal administrative sanction include suspension marketing manufacturing authorization pricing reimbursement successful commercialization product depend availability thirdparty payer reimbursement cost product relate treatment medical service market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price include rebate require pay medicaid agency discount require pay b cover entity result price increase implement time time certain product limit effect net product sale certain market addition standard reimbursement structure adequately reimburse innovative therapy product mature pricing pressure private insurer government payer result reduction net product price new brand generic product introduce major market ability maintain pricing market share affect information item risk factor exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law anti kickback law illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimburse federal healthcare program include purchase prescription particular drug false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim addition fda regulate write verbal communication product addition federal law state consumer protection false claim law breadth statutory provision attention give law enforcement authority sale marketing patient support medical clinical public affair activity subject scrutiny law example recently enhance scrutiny government enforcement authority companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance reimbursement support offering clinical education program promotional speaker program similarly europe interaction pharmaceutical company physician subject strict law regulation industry selfregulation code conduct physician code professional conduct applicable include eu member states anticorruption law uk bribery act addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect unlawful act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program disagree government perspective violate rule guidance similar violation competitor negatively impact reputation industry increase governmental public scrutiny business product healthcare reform federal state government continue propose pass legislation design regulate healthcare industry include legislation seeks indirectly directly regulate pharmaceutical drug pricing information item risk factor impact evolve law regulation legislative regulatory action applicable health care industry environment subject number law regulation require compliance federal state local regulation protection environment regulatory landscape continue evolve anticipate additional regulation future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position information subject information requirement securities exchange act exchange act file periodic report proxy information statement information sec sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically sec website wwwgileadcom link investors website sec filing section available follow filing free charge soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act website reference provide document convenience content reference website constitute incorporate reference annual report item risk factor evaluate business carefully consider follow discussion material risk event uncertainty investment speculative risky addition information annual report manifestation follow risk uncertainty circumstance able accurately predict materially adversely affect business operation growth reputation include commercial scientific reputation product prospect product pipeline sale operate financial result financial condition cash flow liquidity stock price note factor investor permit private security litigation reform act possible predict identify factor operation affect factor event uncertainty presently know currently consider present significant risk operation consider follow risk complete statement potential risk uncertainty face product commercialization risk certain product subject additional heighten risk hiv product receive substantial portion revenue sale product treatment prevention hiv infection sale hiv product account approximately total product sale unable sustain increase sale hiv product number reason include market share gain competitive product include generic inability introduce new hiv medication necessary remain competitive case need scale operation include future drug development spending research development rd effort example hiv product contain tenofovir alafenamide taf belong nucleoside class antiviral therapeutic change treatment paradigm hiv cause nucleosidebase therapeutic fall favor veklury face risk relate supply distribution veklury approve food drug administration fda october treatment patient hospitalize coronavirus disease covid january treatment nonhospitalize adult adolescent patient high risk progression severe covid include hospitalization death utilization veklury largely track rate covid hospitalization unable accurately predict revenue supply need short long term dynamic nature pandemic include availability uptake effectiveness vaccine alternative treatment covid fluctuate hospital utilization rate emergence new variant timing surge infection accurately forecast demand manufacture veklury level sufficient meet demand experience product shortage build excess inventory write remain subject significant public attention scrutiny complex decision clinical datum supply allocation distribution pricing veklury affect corporate reputation cell therapy advance novel personalize therapy yescarta tecartus chimeric antigen receptor car cell therapy create significant challenge include educate certify medical personnel procedure potential effect cytokine release syndrome neurologic toxicity compliance risk evaluation mitigation strategy program require fda secure sufficient supply medication manage effect tocilizumab corticosteroid available sufficient quantity adequately control effect andor detrimental impact efficacy cell therapy develop maintain robust reliable process engineering patient cell facility infuse patient conditioning patient chemotherapy advance administer therapy increase risk adverse effect use engineer cell potential cancer treatment recent development broadly accept physician patient hospital cancer treatment center payer medical community fda approve cell therapy include yescarta tecartus continue demonstrate medical community potential advantage cell therapy compare exist future therapeutic challenge relate reimbursement yescarta tecartus exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure rely thirdparty site collect patient white blood cell know apheresis center shipper courier hospital logistical collection patient white blood cell ultimate delivery yescarta tecartus patient vendor encounter disruption difficulty result product loss regulatory action apheresis center choose participate quality certification process unable complete certification timely manner delay constrain manufacturing commercialization effort operate new automate manufacturing facility frederick maryland facility pende fda approval commercial manufacturing obtain approval manufacture product automate facility commercial scale result able produce obtain supply sufficient satisfy demand product unable meet product demand difficulty meet sale forecast product plan manufacture facility success depend develop commercialize new product expand indication exist product unable launch commercially successful new product new indication exist product business adversely impact launch commercially successful product necessary grow business cover substantial rd expense offset revenue loss exist product lose market share factor competition loss patent exclusivity difficulty uncertaintie inherent drug development introduction new product product development cycle characterize significant investment resource long lead time unpredictable outcome nature develop medicine human use expend significant time resource product pipeline assurance recoup investment effort commercially successful high rate failure inherent discovery development new product failure occur point process include late process substantial investment face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory unable accurately predict demand product include uptake new product demand depend number factor example product demand adversely affect physician benefit product additionally nonretail sector united states include government institution include state aids drug assistance program department veterans affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure annual grant cycle federal state fund cause purchasing pattern reflect patient demand product expect continue experience fluctuation purchase pattern nonretail customer light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel continue trend future sell distribute product united states exclusively wholesale channel year end december approximately product sale united states wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation wholesaler enter inventory management agreement estimate determine endus demand completely effective match inventory level actual endus demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match endus demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition increase competition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order endus demand change addition observe strong wholesaler subwholesaler purchase product fourth quarter typically result inventory drawdown wholesaler subwholesaler subsequent quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer new brand generic product enter major market affect ability maintain pricing market share product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing number company pursue development technology competitive exist product research program compete company include large pharmaceutical biotechnology company specialize pharmaceutical firm act independently company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program adversely impact competitor gain market share result new technology commercialization strategy exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure product reimbursement successful commercialization product depend availability thirdparty payer reimbursement cost product relate treatment medical service market sell product government health authority private health insurer organization generally provide reimbursement product mature pricing pressure private insurer government payer result reduction net product price legislative regulatory action affect government prescription drug procurement reimbursement program occur relatively frequently example september fda issue final rule implement pathway importation certain prescription drug canada rule subject ongoing litigation adversely impact legislative regulatory action difficult predict impact use reimbursement product product pricing discount rebate united states european union eu significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product services united states volume drug pricingrelate bill dramatically increase recent year example congress enact law require manufacturer refund certain amount discard drug singleuse vial begin eliminate exist cap medicaid rebate amount begin congress propose bill require department health human service negotiate price certain drug impose inflationbase rebate medicare b drug list price drug grow fast inflation increase manufacturer contribution medicare benefit phase addition state legislature consider pass law legislation seeks indirectly directly regulate pharmaceutical drug pricing require manufacturer publicly report proprietary pricing information create review board price state agency encourage use generic drug initiative legislation cause add pricing pressure product result impact business uncertain country outside united states include eu member states establish complex lengthy procedure obtain price approval coverage reimbursement periodically review pricing reimbursement decision outcome review predict adverse effect pricing reimbursement medicinal product eu member states reduction price medicinal product member state affect price member state negative impact financial result substantial portion product sale subject significant discount list price include rebate require pay state medicaid agency discount provide b cover entity change b program medicaid program federal state level material adverse effect business example december center medicare medicaid services cms issue final rule certain change calculation rebate medicaid drug rebate program change effective january final rule change requirement exclude manufacturer copay coupon medicaid good price change subject ongoing litigation change effect substantially increase medicaid rebate obligation decrease price charge b cover entity continue growth b program limit price charge increase percentage sale addition standard reimbursement structure adequately reimburse innovative therapy example begin fiscal year cms establish new severityadjuste diagnosisrelate group drg medicare inpatient reimbursement car product yescarta tecartus new drg significantly high base payment prior drg payment available sufficient reimburse hospital cost care patient receive yescarta tecartus reimbursement align account treatment cost medicare beneficiary deny access misalignment impact willingness hospital offer therapy doctor recommend therapy additionally eu barrier reimbursement individual country limit uptake yescarta tecartus addition estimate rebate require pay connection sale particular quarter base claim datum prior quarter united states actual rebate claim typically payer quarter arrear actual claim payment vary significantly estimate experience adverse impact result importation product low price market distribution illegally divert counterfeit version product price product base local market economic competition differ country country sale country relatively high price reduce product import resold country low price market example sale affect fda permit importation drug canada enter agreement generic drug manufacturer license agreement medicine patent pool unite nationsbacke public health organization allow generic drug manufacturer manufacture generic version certain product distribution certain low middleincome country adversely affect generic version product produce andor distribute agreement export united states europe market high price eu required permit product purchase eu member state sell member state purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter additionally divert product country approve patient source divert product outside legitimate supply chain divert product handled ship store inappropriately affect efficacy product harm patient adversely impact aware existence supplier world source product generic version product gilead authorization sell use country product approve result patient risk take unapproved medication purport potency claim contain harmful substance adversely impact party illegally distribute sell continue illegally distribute sell illegally divert counterfeit version medicine meet rigorous quality standard manufacturing supply chain example ongoing investigation coordination marshal local law enforcement recently execute courtordere seizure location state seize thousand bottle gileadlabele medication counterfeit supply chain documentation include bottle label biktarvy descovy investigation reveal pharmaceutical distributor authorize gilead sell gilead medicine sell independent pharmacy nationwide purport genuine gilead medicine source illegal counterfeiting scheme illegally divert counterfeit medicine pose risk patient health safety action stop prevent distribution sale illegally divert counterfeit version medicine world costly unsuccessful adversely affect reputation business include product revenue financial result product development supply chain risk face risk clinical trial include potential unfavorable result delay anticipate timeline disruption require demonstrate safety efficacy product candidate develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product face numerous risk uncertaintie clinical trial result delay prevent completion development approval product candidate risk uncertainty include challenge clinical trial protocol design ability enroll patient clinical trial possibility unfavorable inadequate trial result support development product candidate include failure meet trial primary endpoint safety issue arise clinical trial need modify delay clinical trial perform additional trial example recently announce clinical hold place fda clinical trial evaluate injectable lenacapavir lenacapavir combination islatravir magrolimab include combination azacitidine result unable successfully complete clinical trial anticipate timeline base trial result possible fda regulatory authority approve product candidate market approval include significant limitation product use addition clinical trial involve commercial product raise new safety issue exist product adversely impact business strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline product candidate successfully commercialize unable recoup significant rd clinical trial expense incur anticipate continue expansion clinical pipeline include multiple plan phase study initiation oncology virology expect expend significant time resource clinical trial activity assurance recoup investment effort commercially successful risk associate use party clinical trial activity extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit train program management patient enrollment ongoing monitoring site management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect face manufacture difficulty delay interruption include thirdparty manufacturer corporate partner product manufacture facility thirdparty manufacturer corporate partner result complex highly regulate manufacturing process depend thirdparty manufacturer corporate partner perform manufacturing activity effectively timely basis majority active pharmaceutical ingredient drug product party independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency ema comparable regulation jurisdiction manufacture operation subject routine inspection regulatory agency adverse development affect result manufacturing operation operation thirdparty manufacturer corporate partner result shipment delay inventory shortage lot failure product withdrawal recall interruption commercial supply product need inventory writeoff incur charge expense product fail meet specification quality standard undertake costly remediation effort seek costly manufacturing alternative development increase manufacturing cost cause lose revenue market share damage reputation addition manufacturing issue cause delay clinical trial application regulatory approval example unable remedy deficiency cite fda regulatory agency inspection exist product time regulatory approval product candidate development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country business adversely affect approval product candidate delay production product interrupt able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture sell product unable purchase sufficient quantity material find suitable alternative material timely manner development effort product candidate delay ability manufacture sell product limited supplier key component material name new drug application marketing authorization application file regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control maintain compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product candidate development clinical trial product material utilize operation manufacture supplier facility able replace timely manner commercially reasonable term problem single supplier facility depend include event disaster earthquake equipment failure difficulty negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result encounter difficulty ability conduct clinical trial product candidate manufacture sell product impair regulatory legal risk operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda ema comparable regulatory agency country file anticipate file marketing approval additional country additional indication product year future marketing application file approve regulatory authority timely basis marketing approval grant product significant limitation use state certainty product candidate development approve launch able develop license acquire additional product candidate product product launch commercially successful manufacture sell product subject extensive regulation review example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk certain circumstance required implement risk evaluation mitigation strategy program product include medication guide patient package insert communication plan healthcare provider restriction distribution use product element fda deem necessary assure safe use drug discovery previously unknown problem market product product candidate include safety resistance drug interaction issue problem manufacture safety report promotional activity result regulatory approval delay deny grant significant restriction product include limitation withdrawal product market failure comply requirement impose fda result significant civil monetary penalty fine suspension regulatory approval product recall seizure product criminal prosecution impact evolve law regulation legislative regulatory action applicable health care industry health care industry subject federal state international law regulation pertain drug reimbursement rebate price report health care fraud abuse datum privacy security united states law include antikickback false claim law law regulation relate medicare medicaid programs federal state program medicaid rebate statute law regulate write verbal communication product individual state law relate pricing sale marketing practice health insurance portability accountability act federal state law relate privacy security health information actual allege violation law relate regulation punishable criminal andor civil sanction include instance substantial fine civil monetary penalty exclusion participation federal state health care program include medicare medicaid department veterans affairs department defense health program action executive oversee business significant remediation measure negative publicity consequence law regulation broad scope subject change evolving interpretation require incur substantial cost associate compliance alter sale marketing practice result impact business uncertain material addition government price report payment regulation complex continually assess method calculate report pricing accordance obligation methodology calculation inherently subjective subject review challenge government agency disagree interpretation government disagree report calculation need restate previously report datum subject additional financial legal liability continue enhance scrutiny companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance enhance scrutiny government reimbursement patient support offering clinical education program promotional speaker program agent vendor deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product description government investigation relate litigation note commitment contingency note consolidated financial statement include ii item annual report subject risk significant safety issue arise market product product candidate additional study conduct subsequent obtaining marketing approval product product long period time patient include patient underlie health problem patient take medicine expect continue find new issue relate safety resistance drug interaction issue require change product label additional warning contraindication narrow indication halt sale product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action success depend significant degree ability obtain defend patent intellectual property right domestically internationally operate infringe patent proprietary right party patent proprietary right important business business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology success depend significant degree ability obtain patent license patent right preserve trade secret internal knowhow defend infringement patent effort invalidate operate infringe intellectual property patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application cover technology participate litigation postgrant proceeding patent trademark office proceeding determine right patent validity patent grant litigation proceeding unpredictable expensive divert management attention operation ultimately successful adversely impact generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application process typically manufacturer seek approval generic drug description anda litigation note commitment contingency note consolidated financial statement include ii item annual report entry generic version product future lead market share price erosion find infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license commercially reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir certain use combination emtricitabine ftc tenofovir disoproxil fumarate tdf taf description pende patent litigation note commitment contingency note consolidated financial statement include ii item annual report furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention adversely affect trade secret internal know technological innovation confidential information know independently discover competitor enter dispute ownership invention face potentially significant liability increase expense litigation government investigation relate product operation involve number litigation investigation disputerelate matter require expend substantial internal financial resource matter require pay significant monetary amount include royalty payment past future sale example february reach agreement viiv healthcare company relate party collectively viiv global resolution pende potential claim relate sale biktarvy pursuant viiv grant gilead broad worldwide license covenant sue relate past present future development commercialization bictegravir gilead agree onetime payment billion ongoing royalty rate future sale biktarvy bictegravir component bictegravircontaining product united states october expect matter continue require high level internal financial resource foreseeable future matter reduce expect continue reduce earning require significant management attention addition testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company limited insurance product liability arise claim exceed coverage description litigation investigation disputerelate matter note commitment contingency note consolidated financial statement include ii item annual report outcome legal proceeding legal proceeding bring investigation investigation initiate disputerelate matter inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief operational risk business future adversely affect outbreak epidemic pandemic contagious disease include ongoing covid outbreak actual threaten outbreak epidemic pandemic contagious disease covid significantly disrupt global operation adversely affect business financial condition result operation example covid pandemic cause significant volatility uncertainty international market result increase risk adverse impact operation include describe addition development discuss ii item management discussion analysis financial condition result operation monitor number risk relate pandemic include follow supply chain pandemic result disruption global supply chain distribution future example quarantine shelterinplace governmental order policy travel restriction airline capacity route reduction safety guideline health impact pandemic impact availability productivity product personnel manufacturer distributor freight carrier necessary component supply chain addition unfavorable change availability cost raw material intermediate material necessary production result high cost disruption supply chain interruption distribution capability clinical trial pandemic adversely affect continue adversely affect certain clinical trial include ability initiate complete clinical trial anticipated timeline ongoing trial clinical trial site impose restriction patient visit limit risk possible covid exposure experience issue participant compliance clinical trial protocol result quarantine travel restriction interruption healthcare service risk closure clinical site necessary pandemic relate guidance restriction continue evolve forego reason experience delay new subject enrollment clinical trial course pandemic continue experience overall delay clinical trial risk biased data collection certain clinical trial site remain open result challenge anticipate filing marketing timeline certain product adversely impact regulatory review operation fda ema regulatory agency adversely affect experience delay necessary interaction regulatory authority world include respect anticipate filing factor result pandemic adversely impact ability launch new commercial product access healthcare providers pandemic limited patient ability willingness access seek care healthcare provider initiate continue therapy result low demand product course pandemic particularly respect hepatitis c virus hcv treatment hiv treatment prevention example observe low level patient visit test volume hcv result few patient start addition times pandemic see low level screen diagnosis hiv result few treatment initiation high level discontinuation result reduction prescription refill increase level unemployment times pandemic experience shift payer mix governmentfunde coverage uninsured segment field personnel reduce access healthcare personnel pandemic include few inperson interaction adversely impact continue adversely impact commercial activity employee face risk relate health safety morale productivity employee include safe occupancy site pandemic fourth quarter transition returntosite phase flexible location employee job site enhancement risk protocol include health screening covid testing vaccine requirement guarantee maintain continued safe occupancy site adversely impact employee recruitment retention onsite employee test positive covid lead mandatory quarantine potential site shutdown financial pandemic continue adverse financial impact short term potentially particular hcv hiv business continue adversely impact example observe reduction overall hcv treatment hiv treatment hiv preexposure prophylaxis prep volume times pandemic uncertain volume return pre pandemic level continue experience fluctuate revenue infection rate rise fall pandemic restriction periodically tighten ease experience continue experience volatility shortterm revenue fluctuation inventory channel purchase pandemic additional unexpected expense relate pandemic negatively affect result operation factor overall uncertainty disruption cause pandemic result increase volatility decrease predictability result operation volatility stock price pandemic amplify risk describe risk factor section annual report extent pandemic impact business result depend future development uncertain predict confidence include potential future wave pandemic new variant virus impact severity duration pandemic development distribution effectiveness public acceptance vaccine ongoing future action take contain pandemic face risk associate global operation global operation accompany certain financial political economic risk include list foreign currency exchange year end december approximately product sale outside united states significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate overall net receiver foreign currency benefit weak dollar adversely affect strong dollar hedging program eliminate exposure currency fluctuation adversely impact dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation interest rate inflation hold interestgenerate asset interestbeare liability include availableforsale debt security senior unsecured note credit facility fluctuation interest rate expose increase financial risk addition change inflation rate adversely impact business financial result antibribery subject foreign corrupt practice act similar worldwide antibribery law govern international operation respect payment government official international operation heavily regulate require significant interaction foreign official operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital statecontrolled manner different local custom possible certain practice challenge law addition internal control policy procedure protect reckless criminal act commit employee agent enforcement activity antibribery law subject administrative legal proceeding action result civil criminal sanction include monetary penalty exclusion healthcare program risk inherent conduct global business include restrictive government action intellectual property foreign asset nationalization expropriation imposition compulsory license similar action include waiver intellectual property protection protective economic policy take foreign government trade protection measure import export licensing requirement result imposition trade sanction similar restriction united states government business interruption stem natural manmade disaster climate change earthquake hurricane flooding fire extreme heat drought actual threaten public health emergency effort take party prevent mitigate disaster public safety power shutoff facility shutdown uninsured inadequately insure example corporate headquarters foster city certain rd manufacturing facility locate california seismically active region event major earthquake carry adequate earthquake insurance significant recovery time require resume operation political instability disruption geographic region operate regardless cause include war terrorism social unrest political change aspiration goal disclosure relate environmental social governance esg matter expose numerous risk include risk reputation stock price institutional individual investor increasingly esg screen criterion determine gilead qualify inclusion investment portfolio frequently ask investor stakeholder set ambitious esg goal provide new robust disclosure goal progress goal matter interest esg stakeholder response adapt tracking report corporate responsibility program evolving esg framework establish announce goal objective relate esg matter goal statement reflect current plan aspiration guarantee able achieve effort accomplish accurately report goal objective present numerous operational reputational financial legal risk material negative impact include reputation stock price ability achieve goal objective include respect environmental diversity initiative subject numerous risk outside control example risk include availability cost low noncarbonbase energy source technology evolve regulatory requirement affect esg standard disclosure availability supplier meet sustainability diversity standard ability recruit develop retain diverse talent labor market impact organic growth acquisition disposition business operation standard tracking report esg matter relatively new harmonized continue evolve selection disclosure framework seek align reporting standard change time time result lack consistent meaningful comparative datum period period addition process control comply evolve standard identify measure report esg metric interpretation reporting standard differ standard change time result significant revision goal report progress achieve goal esg practice meet evolve investor stakeholder expectation standard reputation ability attract retain employee attractiveness investment business partner acquiror negatively impact similarly failure perceive failure pursue fulfill goal target objective satisfy reporting standard timeline announce similar negative impact expose government enforcement action private litigation depend relationship party sale marketing performance technology development logistic commercialization product failure maintain relationship poor performance company dispute party negatively impact business rely number collaborative relationship party sale marketing performance certain territory example collaboration arrangement janssen sciences ireland uc odefsey compleraeviplera symtuza country rely international distributor sale certain product relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline specialized technical nature business failure attract develop retain highly qualified personnel adversely impact future success depend large continue ability attract develop retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization ability depend maintain strong workplace culture attractive employee addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit face competition personnel company university public private research institution government entity organization additionally change immigration work authorization law regulation difficult employee work transfer jurisdiction operate significant cybersecurity incident rise legal liability regulatory action datum protection privacy law adversely affect business operation dependent information technology system infrastructure datum include kite konnect platform critical maintain chain identity chain custody yescarta tecartus multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion ransomware attack likewise datum privacy security breach employee result exposure sensitive datum include intellectual property trade secret personal information employee patient customer business partner unauthorized person public cybersecurity incident increase frequency sophistication intensity include covid pandemic cybersecurity incident include example deployment harmful malware ransomware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business technology partner face similar risk security breach system adversely affect security posture like company experience cybersecurity incident include data breach service interruption cybersecurity incident occur respond address accordance applicable governmental regulation legal requirement include cybersecurity protocol assurance effort response cybersecurity incident investment protect information technology infrastructure datum shield significant loss potential liability prevent future interruption breach system cybersecurity incident cause loss critical sensitive information include personal information rise legal liability regulatory action datum protection privacy law regulator globally impose new datum privacy security requirement include new great monetary fine privacy violation example general datum protection regulation gdpr establish regulation handle personal datum noncompliance gdpr result monetary penalty percent worldwide revenue addition new domestic datum privacy security law california consumer privacy act california privacy rights act law passed similarly introduce requirement respect personal information noncompliance law result liability private action subject statutorily define damage event certain data breach enforcement change new law regulation associate enhance protection personal information include case healthcare datum personal information greatly increase cost provide product service prevent offer certain service jurisdiction operate strategic financial risk subject risk associate engage business acquisition licensing arrangement collaboration option equity investment asset divestiture strategic transaction engage future engage transaction business strategy identify suitable transaction future complete transaction timely manner costeffective basis realize expect benefit successful make acquisition closing licensing arrangement collaboration product intellectual property technology acquire license successful require significantly great resource investment anticipate annual impairment testing goodwill indefinitelive intangible asset fourth quarter early impairment indicator exist require generally accept accounting principle need recognize impairment charge product intellectual property technology acquire license successful option structure deal assurance elect exercise option right possible disagreement uncertainty circumstance arise include respect option right appropriately trigger hinder ability realize expect benefit equity investment strategic transaction connection collaboration arcus biosciences inc galapagos nv value equity investment fluctuate decline value successful execution implementation transaction financial condition cash flow result operation adversely affect stock price decline pay substantial amount cash incur additional debt finance strategic transaction additional indebtedness low cash balance result downgrade credit rating limit ability borrow additional fund refinance exist debt favorable term increase vulnerability adverse economic industry condition reduce financial flexibility continue capital investment stock repurchase dividend payment example result cash debt issue connection acquisition immunomedics inc sp global rating downgrade credit rating adversely impact failure overcome additional risk change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction economic political condition country actively consider change exist tax law predict form timing change effective tax rate affect change mix earning country differ statutory tax rate change valuation defer tax asset liability introduction new taxis change tax law regulation administrative practice interpretation include united states germany ireland subject examination tax return tax matter internal revenue service tax authority foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction adversely affect resolution exposure report period item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing rd activity rd facility emeryville oceanside santa monica california seattle washington morris plain new jersey frederick maryland edmonton canada dublin ireland principal manufacturing facility el segundo la verne oceanside san dimas california edmonton canada cork ireland hoofddorp netherland information manufacture facility item business manufacture facility global operation include office europe north america asia south america africa australia middle east believe exist property include own lease site adequate suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include ii item annual report item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild february approximately stockholders record common stock performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index sp index nasdaq biotechnology index nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file security exchange commission sec incorporate reference filing securities act amend securities act securities exchange act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december assume dividend reinveste equity compensation plan information follow table provide certain information respect equity compensation plan effect december number common share remain available future number common share weightedaverage issuance equity issue exercise exercise price compensation plan outstanding option warrant outstanding option exclude security million share amount right warrant right reflect column plan category b c equity compensation plan approve security holder equity incentive plan employee stock purchase plan total equity compensation plan approve security holder equity compensation plan approve security holder total account million restrict stock unit performance share award unit phantom share exercise price grant equity incentive plan include award share previously issuable immunomedics inc amend restate longterm incentive plan immunomedic plan assume connection acquisition immunomedics inc subsequently merge equity incentive plan employee stock purchase plan participant permit purchase common stock discount certain date payroll deduction predetermine purchase period accordingly number determinable include award share issuable seven inc equity incentive plan assume connection acquisition seven inc seven subsequently amend restate equity incentive plan material feature gilead sciences inc equity incentive plan seven inc equity incentive plan originally establish seven june connection gilead acquisition seven april gilead assume seven inc equity incentive plan amend restate gilead sciences inc equity incentive plan plan plan intend help gilead secure retain service eligible award recipient provide incentive person exert maximum effort success gilead affiliate provide mean eligible recipient benefit increase value gilead common stock april employee consultant seven immediately prior date employee consultant gilead hire follow date eligible receive grant new award plan plan provide award incentive stock option nonqualifie stock option generally exercise price equal fair market value common stock date grant stock appreciation right restrict stock award restrict stock unit award performance stock award stock award performance cash award april aggregate number share common stock issuable plan date april gilead grant restrict stock unit performance share award unit stock option plan type equity award outstanding plan december million share gilead common stock remain available issuance plan issuer purchase equity security quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction repurchase program start april quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction repurchase retire million share common stock million open market transaction program december remain authorize repurchase program billion table summarize stock repurchase activity month end december maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program thousand dollar thousand million october october november november december december total difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation dividend year end december pay quarterly dividend expect continue pay quarterly dividend time future dividend subject declaration board director additional information include item management discussion analysis financial condition result operation consolidate financial statement item reserve item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor additional information relate comparison result operation year include item management discussion analysis financial condition result operation file securities exchange commission sec consolidated financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead biopharmaceutical company pursue achieve breakthrough medicine decade goal create healthy world people commit advance innovative medicine prevent treat lifethreatening disease include hiv viral hepatitis cancer operate country worldwide headquarters foster city california portfolio market product include ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approve united states sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement business highlight deliver strong financial performance veklury continue play critical role address coronavirus disease covid pandemic veklurys performance help mitigate impact covid part business include hiv chronic hepatitis c virus hcv franchise impact october loss exclusivity truvada atripla united states despite transitory headwind underlie demand virology portfolio remain strong lead continued growth biktarvy franchise receive increase contribution oncology franchise experience growth trodelvy cell therapy franchise continue expand strengthen commercial portfolio clinical pipeline therapeutic focus area drive future growth potential announce additional filing regulatory approval addition invest internal pipeline program continue enter leverage exist strategic collaboration partnership include opt additional pipeline asset collaboration arcus biosciences inc arcus develop foundation sustainable diversified business viral disease october food drug administration fda approve new lowdose tablet dosage form biktarvy pediatric patient weigh kg kg virologically suppress new antiretroviral therapy august marketing authorization application lenacapavir investigational longacte hiv capsid inhibitor fully validate evaluation european medicine agency ema june fda grant approval new oral pellet formulation epclusa expand pediatric indication treat child young year age chronic hcv june submit new drug application fda lenacapavir investigational longacte agent development treatment hiv people limit therapy option march enter agreement merck sharp dohme corp merck subsidiary merck co inc jointly develop commercialize longacte investigational treatment hiv combine gilead investigational capsid inhibitor lenacapavir merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir march complete acquisition myr gmbh myr acquisition provide hepcludex conditionally approve ema treatment chronic hepatitis delta virus hdv adult compensate liver disease covid january fda grant expedite approval veklury treatment nonhospitalize adult adolescent patient high risk progression severe covid include hospitalization death december european commission grant approval expand indication veklury use early stage disease adult patient require supplemental oxygen increase risk progress severe covid april announce provide assistance support expansion local manufacturing capacity remdesivir india donate active pharmaceutical ingredient ii donate minimum vial veklury remdesivir government india oncology cell therapy january fda approve update prescribing information yescarta include use prophylactic corticosteroid approve indication yescarta chimeric antigen receptor car tcell therapy information label help physician manage potentially prevent treatment effect october fda approve tecartus treatment adult patient relapse refractory bcell precursor acute lymphoblastic leukemia tecartus car cell therapy approve adult september kite gilead company kite submit supplemental biologic license application fda yescarta expand current indication include treatment adult relapse refractory large bcell lymphoma lbcl secondline set august kite appia bio inc enter collaboration license agreement research develop hematopoietic stem cell derive cell therapy direct hematological malignancy june kite enter research collaboration license agreement shoreline biosciences inc develop novel allogeneic cell therapy variety cancer target june fosun kite biotechnology co ltd joint venture kite shanghai fosun pharmaceutical group co ltd receive approval china national medical products administration axicabtagene ciloleucel treatment adult patient relapse refractory lbcl china march fda grant accelerated approval yescarta treatment adult patient relapse refractory follicular lymphoma fl january enter clinical trial collaboration agreement merck evaluate trodelvy combination merck antiprogramme death receptor pd therapy keytruda firstline set patient nonsmall cell lung cancer nsclc november european commission grant marketing authorization trodelvy treatment metastatic triplenegative breast cancer tnbc adult patient unresectable metastatic tnbc receive prior systemic therapy advanced disease november exercise option program clinicalstage portfolio arcus include antitigit molecule domvanalimab ab clinical candidate etrumadenant dual adenosine aaab receptor antagonist quemliclustat small molecule cd inhibitor transaction close december october enter clinical trial collaboration supply agreement merck evaluate efficacy trodelvy combination keytruda firstline treatment patient locally advanced metastatic tnbc september health canada approve trodelvy treatment adult patient unresectable locally advanced metastatic tnbc receive therapy metastatic disease canada join australia great britain switzerland united states country approve trodelvy use project orbis global collaborative review program high impact oncology marketing application participate country april fda grant accelerated approval trodelvy use adult patient locally advanced metastatic urothelial cancer uc new indication april fda grant approval trodelvy adult patient unresectable locally advanced metastatic tnbc announce discuss update detail press release available website wwwgileadcom reader encourage review press release available website mention content reference website constitute incorporate reference annual report form k financial highlight million percentage share amounts change total revenue net income attributable gilead nm net income share attributable gilead common stockholder dilute nm nm meaningful total revenue increase billion compare billion primarily increase sale veklury fdaapprove treatment hospitalize patient covid increase reflect continue growth biktarvy geography continue uptake trodelvy cell therapy chronic hepatitis b virus hbv hdv product increase partially offset decrease truvada atripla sales united states expect primarily continued generic competition follow october loss exclusivity united states net income attributable gilead billion diluted earning share compare million diluted earning share increase primarily lower acquire inprocess research development iprd charge revenue growth lower unrealized loss equity investment partially offset billion charge settlement relate bictegravir litigation charge million relate arcus collaboration optin acquire iprd expense billion primarily relate acquisition seven collaboration investment enter year arcus pionyr immunotherapeutics inc pionyr tango therapeutics inc tango tizona therapeutics inc tizona jounce therapeutics inc jounce strategy outlook purpose deliver lifechange medication patient need scientific breakthrough innovation strong operational execution strategic ambition bring transformative therapy patient ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priority reflect deliver ambition expand internal external innovation ii strengthen portfolio strategy decision make iii increase patient benefit access iv continue evolve culture continue focus execute strategy expand diversify commercial portfolio clinical pipeline therapeutic focus area virology oncology inflammation specifically plan significantly increase clinical development study novel oncology portfolio maintain leadership antiviral medication work hiv hepatitis covid pandemic emerge virus collaboration arcus provide additional opportunity develop foundation sustainable diversified business expand product pipeline continue focus employee evolution culture effort promote racial equity social justice additionally expect maintain rigorous focus discipline expense management covid pandemic continue impact business broad market dynamic expect revenue growth product sale exclude veklury compare hiv product sale continue recover covid pandemic demonstrate yearoveryear growth financial impact truvada atripla loss exclusivity largely start second quarter expect oncology business include cell therapy trodelvy contribute growth veklury sale generate highly dynamic complex global environment continue evolve result veklury sale subject significant volatility uncertainty future product demand depend nature covid pandemic include duration infection rate hospitalization availability adoption alternative therapie vaccine anticipate yearoveryear decline veklury product sale expect veklury continue play key role pandemic contribute meaningfully revenue heavily weight begin year ability deliver strategy subject number uncertainty include limited effect covid pandemic remain unpredictable uncertainty time future veklury sale continuation uncertain global macroeconomic environment ability realize potential benefit acquisition collaboration license arrangement ability initiate progress complete clinical trial currently anticipate timeframe include result current future hold clinical trial possibility unfavorable result new ongoing clinical trial ability submit new drug application new product candidate expand indication currently anticipate timeline ability receive regulatory approval timely manner market share price erosion cause introduction generic loss exclusivity product higher anticipate effect loss exclusivity truvada atripla slow anticipate growth biktarvy trodelvy vemlidy cell therapy product inaccuracy patient start estimate additional pricing pressure payer competitor increase discount chargeback rebate ongoing contract future negotiation commercial government payer potential government action effect lower price largerthan anticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation revenue follow table summarize periodoverperiod change revenue year end december year end december millions percentage europe international total europe international total change product sale hiv veklury hcv hbvhdv cell therapy trodelvy nm total product sale royalty contract revenue total revenue nm meaningful product sale hiv hiv product sale decrease billion compare billion anticipate decline sale volume truvada emtricitabine ftc tenofovir disoproxil fumarate tdfbase product drive continued generic competition follow october loss exclusivity truvada atripla united states truvada atripla product sale billion low compare decrease impact low sale genvoya drive decrease volume worldwide primarily patient switch biktarvy decline partially offset increase biktarvy product sale worldwide drive high demand high net average selling price drive favorable change estimate government rebate discount united states expect hiv business continue recover covid pandemic expect impact truvada atripla loss exclusivity largely start second quarter veklury veklury product sale billion compare billion veklury commercially available quarter result partial year sale increase attributable high hospital demand worldwide sale veklury generally affect covid relate rate infection hospitalization vaccination availability uptake effectiveness alternative treatment covid result future sale veklury difficult predict hcv hcv product sale decrease billion compare billion primarily low demand drive few patient start worldwide impact covid pandemic slight increase hcv sale europe favorable change estimate government rebate offset revenue decrease associate low demand hbv hdv hbv hdv product sale increase million compare million primarily high vemlidy product sale high demand geography partially offset low viread product sale international location hepcludex sale million launch activity continue europe follow quarter acquisition myr cell therapy cell therapy product sale include yescarta tecartus increase million compare million growth primarily july launch tecartus united states treatment adult patient relapse refractory mantle cell lymphoma mcl december launch tecartus mcl europe result partial year sale increase drive continued high demand yescarta worldwide lbcl volume growth relate approval yescarta fl united states trodelvy trodelvy product sale increase million compare million obtain trodelvy fourth quarter acquisition immunomedic result partial year sale addition revenue include continue uptake trodelvy follow regulatory approval metastatic tnbc united states europe accelerate approval metastatic uc united states product sale product sale include ambisome cayston jyseleca letairis ranexa zydelig billion remain flat compare ambisome sale volume increase high demand geography outside united states increase offset low letairis sale united states anticipate continued generic competition follow loss exclusivity grosstonet deduction record product sale net estimate government rebate chargeback cash discount prompt payment distributor fee sale return relate cost deduction total billion gross product sale compare billion gross product sale reduction drive change product mix primarily high veklury sale billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee sale return relate cost foreign currency exchange impact total product sale generate outside united states respectively generally face exposure movement foreign currency exchange rate primarily euro use foreign currency exchange contract hedge portion foreign currency exposure foreign currency exchange net hedge favorable impact total product sale million base comparison foreign currency exchange rate largely drive eurobase product sale follow table summarize periodoverperiod change product sale year end december year end december millions percentage europe international total europe international total change hiv product descovy ftctaf base product biktarvy descovy genvoya odefsey revenue share symtuza total descovy ftctaf base product truvada ftctdf base product atripla compleraeviplera stribild truvada total truvada ftctdf base product hiv total hiv veklury hcv product ledipasvirsofosbuvir sofosbuvirvelpatasvir hcv total hcv hbvhdv product vemlidy viread hbvhdv nm total hbvhdv cell therapy product tecartus nm yescarta total cell therapy trodelvy nm product ambisome letairis ranexa zydelig total total product sale nm meaningful represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland unlimited company include emtriva tybost amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include vosevi sovaldi include hepcludex hepsera include cayston jyseleca cost expense follow table summarize periodoverperiod change cost expense million percentage change cost good sell product gross margin bps research development rd expense acquire iprd expense sell general administrative sga expense product gross margin product gross margin decrease compare primarily billion charge settlement relate bictegravir litigation increase million acquisitionrelate expense amortization finitelive intangible asset recognition inventory stepup charge primarily drive acquisition immunomedic myr product gross margin impact high inventory writedown charge change product mix increase partially offset low royalty expense low sale product contain emtricitabine elvitegravir reversal previously record million litigation accrual follow favorable court decision relate axicabtagene ciloleucel research development expense rd expense consist primarily clinical study perform contract research organization material supply payment collaborative arrangement include milestone payment license fee expense reimbursement collaboration partner personnel cost include salary benefit stockbase compensation expense overhead allocation consist support infrastructure cost manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability technical regulatory successful development market potential available human capital resource consideration continually review rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity believe good support longterm growth business rd expense increase million compare primarily arcus collaboration optin charge million high investment trodelvy magrolimab clinical activity increase partially offset decline approximately million external expense relate winddown completion certain remdesivir clinical studies ii million million charge record connection agreement amend exist arrangement galapago commercialization development jyseleca iii low stockbase compensation expense rd expense include accelerate stockbased compensation expense million relate acquisition immunomedic seven acquire inprocess research development expense acquire iprd expense reflect iprd impairment initial cost externally develop iprd project acquire directly transaction business combination alternative future use include upfront payment relate collaboration initial cost right iprd project acquire iprd expense million relate licensing collaboration investment arrangement enter year acquire iprd expense billion primarily relate acquisition seven collaboration investment enter year arcus pionyr tango tizona jounce sell general administrative expense sga expense relate sale marketing finance human resource legal administrative activity include information technology investment sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale sga expense increase million compare primarily expense million relate donation certain equity security fair value gilead foundation california nonprofit organization foundation increase commercial activity include high promotional marketing activity primarily drive trodelvy sga expense include accelerate stockbased compensation expense million relate acquisition immunomedic seven charge million relate department justice investigation settle quarter interest expense income expense net follow table summarize periodoverperiod change interest expense income expense net million percentage change interest expense income expense net interest expense increase million compare primarily increase borrow relate fourth quarter acquisition immunomedic partially offset low interest expense debt maturity repayment change income expense net compare primarily reflect lower unrealized loss fair value adjustment investment equity security largely drive investment galapago partially offset low interest income change fair value equity security result net unrealized loss million billion year end december respectively income taxis follow table summarize periodoverperiod change income tax expense benefit million percentage income income taxis income tax expense effective tax rate effective tax rate decrease compare primarily billion acquire iprd charge record connection acquisition seven million certain acquire iprd charge nondeductible tax purpose liquidity capital resource cash cash equivalent marketable debt security billion billion december respectively cash flow follow table summarize cash flow activity million net cash provide operating activity invest activity financing activity operate activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity increase billion billion compare increase primarily revenue growth sale veklury high collection receivables investing activity cash investing activity primarily consist purchase sale maturity marketable debt security capital expenditure acquisition include iprd net cash acquire purchase equity security investment cash investing activity billion compare billion decrease cash investing activity primarily decrease cash outflow related acquisition include iprd net cash acquire billion payment quarter acquisition myr compare billion billion payment related acquisition seven immunomedic respectively decrease partially offset net cash generate investing activity relate proceed sale maturity marketable debt security partially fund acquisition financing activity cash financing activity year end december billion compare cash provide financing activity million utilize cash billion debt repayment billion dividend payment million common stock repurchase obtain billion proceed debt finance net issuance cost fund fourth quarter acquisition immunomedic partially offset cash utilize billion dividend payment billion debt repayment billion common stock repurchase debt credit facility summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report choose repay certain longterm debt obligation prior maturity date base assessment current longterm liquidity capital requirement senior unsecured note term loan repay billion debt consist billion senior unsecured note billion senior unsecured term loan facility repay billion senior unsecured note april quarter billion senior unsecured note december quarter additionally repay million senior unsecured note maturity september october exercise option million senior unsecured float rate note million senior unsecured note final maturity date september early repayment total billion principal fourth quarter december exercise option million senior unsecured note final maturity march note repay february new debt issue require comply certain covenant note indenture govern senior unsecured note december violation covenant liability relate future royalty connection acquisition immunomedic assume liability relate funding arrangement originally enter immunomedics rpi finance trust prior acquisition immunomedic liability relate future royalty primarily include longterm debt net consolidated balance sheet note acquisition note consolidated financial statement include item annual report form k additional information credit facility june terminate billion fiveyear revolve credit facility mature revolve credit facility enter new billion fiveyear revolve credit facility mature june revolve credit facility revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding revolve credit facility revolve credit facility contain customary representation warranty affirmative negative covenant event default december compliance covenant capital return program detail stock repurchase program dividend include note stockholder equity note consolidated financial statement include item annual report stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction purchase million million share common stock program million billion respectively december remain authorize repurchase program billion dividend declare pay quarterly cash dividend aggregate billion share common stock billion share common stock respectively february announce board director declare quarterly cash dividend increase share common stock payment date march stockholders record close business march future dividend subject declaration board director capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term material cash requirement continually evaluate liquidity capital resource include access external capital ensure adequately efficiently finance operation december material cash requirement consist primarily repayment outstanding borrowing remain obligation onetime repatriation transition tax tax cut job act settlement relate bictegravir litigation purchase inventory operating lease obligation capital expenditure milestone payment relate collaborative agreement note collaboration arrangement debt credit facility lease commitment contingency income taxis note consolidated financial statement include item annual report additional information anticipate cash requirement relate capital expenditure increase compare prior year work expand site infrastructure capability critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement government rebate chargeback revenue product sale recognize net estimate government rebate chargeback cash discount prompt payment distributor fee sale return provision relate deduction deduction product sale refer grosstonet deduction estimate record period relate product sale occur revenue product sale net deduction record extent significant reversal cumulative revenue recognize probable occurring uncertainty associate grosstonet deduction subsequently resolve government rebate chargeback subject complex estimation process require significant judgment management lag date product sale date relate rebate chargeback claim settle government rebate chargeback include amount payable payer healthcare provider program vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price rebate chargeback estimate primarily base product sale expect payer mix discount rate require significant estimate judgment additionally develop estimate government rebate chargeback consider follow historical estimate payer mix statutory discount requirement contractual term historical claim experience processing time lag estimate patient population know market event trend market research channel inventory datum obtain major wholesaler pertinent internal external information follow table summarize consolidated activity end balance government rebate chargeback account balance decreaseincrease balance end million begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total product sale include impact million change estimate related product sale primarily united states assume high rebate claim government payer segment result covid pandemic anticipate impact materialize assess update estimate report period reflect actual claim current information believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate historically actual government rebate chargeback claim prior period vary estimate government chargeback payable direct customer classify reduction account receivable consolidated balance sheet total million million december respectively note financial information note consolidated financial statement include item annual report additional information government rebate payable party payer healthcare provider generally record accrue government rebate consolidated balance sheet total billion billion december respectively acquisition valuation intangible certain judgment determine transaction account acquisition asset business combination determine substantially fair value gross asset acquire transaction concentrate single asset group similar asset transaction treat acquisition asset evaluate input process output associate acquire set activity asset asset transaction include input substantive process significantly contribute ability create output transaction treat acquisition business account business combination acquisition method accounting require asset acquire liability assume generally record fair value acquisition date excess consideration fair value net asset acquire record goodwill estimate fair value require significant judgment assumption perform impairment testing goodwill annually frequently event change circumstance indicate likely asset impair transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date expense alternative future use addition product development milestone expense achievement valuation intangible asset acquire expect continue acquire intangible asset asset acquisition business combination identifiable intangible asset measure respective fair value acquisition date intangible asset acquire business combination subject potential adjustment measurement period year acquisition date fair value intangible asset generally determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use significant estimate assumption include limited identification product candidate sufficient substance require separate recognition estimate project future cash flow include revenue operate profit relate product product candidate probability technical regulatory success unapproved product candidate consider stage development time resource need complete development approval product candidate appropriate discount rate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire base reasonable estimate assumption give fact circumstance relate valuation date impairment amortization intangible asset intangible asset relate iprd project acquire business combination capitalize indefinitelive intangible asset completion abandonment associate rd effort period asset consider indefinitelive amortize development successfully complete generally occur regulatory approval obtain associate asset deem finitelived amortize respective estimate useful life begin point time primarily straightline basis indefinitelive intangible asset compose iprd project acquire business combination lack regulatory approval time acquisition test impairment annually event change circumstance indicate likely asset impair regulatory approval estimate fair value result complex series judgment future event uncertainty assumption point time acquisition date subsequent impairment assessment date change estimate assumption include time product launch pricing reduction failure obtain anticipate regulatory approval deterioration global financial market unanticipate event circumstance decrease project cash flow increase discount rate potentially result impairment charge eventual realize value acquire iprd project vary fair value date acquisition carry value intangible asset exceed estimate fair value impairment charge record write intangible asset estimate fair value example recognize million impairment charge relate iprd project primarily treatment indolent bcell nonhodgkin lymphoma change estimate market opportunity high rate failure inherent discovery development new product intangible asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration amortization note goodwill intangible asset note consolidated financial statement include item annual report additional information legal contingency party legal action significant describe note commitment contingency note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine material loss reasonably possible disclose possible loss range loss loss estimate time significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change fourth quarter record accrual billion accrue current liability consolidate balance sheet settlement relate bictegravir litigation note commitment contingency note consolidated financial statement include item annual report additional information income taxis estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization defer tax asset report period record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis recognize tax benefit uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize consolidated financial statement particular tax position base large benefit likely realize unrecognized tax benefit utb adjust appropriate change fact circumstance significant amendment exist tax law new regulation interpretation tax authority new information obtain tax examination resolution examination recognize accrue interest penalty appropriate relate utb income tax expense benefit consolidate statement income recent accounting pronouncement new accounting pronouncement issue adopt year end december significance item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk market price reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation country worldwide result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million million respectively realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale debt security senior unsecured note create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december expect maturity total fair million percentage total value asset availableforsale debt security average interest rate liability senior unsecured fix rate note include current portion average interest rate amount represent principal balance addition senior unsecured fix rate note billion fiveyear revolve credit facility mature june amount outstanding fiveyear revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information market price risk hold share common stock certain publicly trade biotechnology company primarily connection license collaboration agreement equity security measure fair value change fair value recognize earning fair value equity security approximately billion billion december respectively change fair value equity security impact volatility stock market change general economic condition factor hypothetical increase decrease stock price equity security increase decrease fair value december approximately million million respectively item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm pcaob d audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income loss consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm stockholder board director gilead sciences inc opinion financial statement audit accompany consolidated balance sheet gilead sciences inc company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note collectively refer consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob companys internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise current period audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate government commercial rebate description matter fully describe note company estimate reduction revenue amount payable payer healthcare providers united states government commercial rebate program period relate sale occur rebate vary product payer individual payer plan know point sale estimate reduction revenue base product sale historical expect payer mix discount rate estimate actual datum adjust current period expectation auditing company estimate reduction revenue rebate complex involve significant judgment particularly assess reasonableness estimate payer mix apply sale period estimate rely heavily historical datum adjust change payer mix expectation time address evaluate test design operating effectiveness company internal control management estimation matter audit review reduction revenue rebate program include control assess payer mix assumption test completeness accuracy datum utilize control accuracy calculation support management estimate test management estimation methodology determine payer mix audit procedure include analytically evaluate management estimate evaluate evidence contrary estimate amount perform sensitivity analysis rate estimate perform comparison actual payment relate amount accrue current prior year valuation inprocess research development intangible asset acquire immunomedics inc description matter december company inprocess research development iprd intangible asset acquire connection acquisition immunomedics inc billion discuss note intangible asset indefinite useful life relate purchase iprd project measure respective fair value acquisition date consider indefinitelive completion abandonment associate rd effort company test indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount auditing impairment test iprd intangible asset acquire immunomedic complex significant judgment require estimate fair value particular fair value estimate require use valuation methodology sensitive significant assumption eg discount rate probability technical regulatory success addressable patient population treatment duration project market share affect expect future market economic condition address evaluate test design operating effectiveness company internal control determination matter audit estimate fair value iprd intangible asset acquire immunomedics example test control management review valuation methodology significant assumption develop fair value estimate test management control validate datum fair value estimate complete accurate test estimate fair value company iprd intangible asset acquire immunomedics audit procedure include evaluate company use appropriate valuation methodology assistance valuation specialist evaluate sensitivity analysis determine assumption great impact overall determination value test completeness accuracy underlie datum audit procedure significant assumption include compare assumption current industry market economic trend historical result company business guideline company industry relevant factor example evaluate probability technical regulatory success consider phase development clinical project company history obtain regulatory approval addition evaluate expect addressable patient population compare company estimate external industry forecast ernst young llp serve company auditor san jose california february gilead sciences inc consolidated balance sheet december millions share amount asset current asset cash cash equivalent shortterm marketable debt security account receivable net inventory prepay current asset total current asset property plant equipment net longterm marketable debt security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue current liability current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable deferred tax liability longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share authorize share issue outstanding december additional paidin capital accumulate comprehensive income loss retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income year end december millions share amount revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense acquire inprocess research development expense sell general administrative expense total cost expense income operation interest expense income expense net income income taxis income tax expense benefit net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute accompany note gilead sciences inc consolidated statement comprehensive income loss year end december millions net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt security net unrealize gain loss net tax reclassification net income net tax net change cash flow hedge net unrealized gain loss net tax reclassification net income net tax net change comprehensive income loss comprehensive income loss comprehensive loss attributable noncontrolle interest comprehensive income loss attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity gilead stockholder equity accumulate common stock additional total paidin comprehensive retain noncontrolle stockholder million share amount share capital income loss earning interest equity balance december cumulative effect adoption new accounting standard net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december cumulative effect adoption new accounting standard change noncontrolle interest net income loss comprehensive income loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december net income loss comprehensive income loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december accompany note gilead sciences inc consolidated statement cash flow year end december million operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense defer income taxis net gain loss equity security acquire inprocess research development expense inprocess research development impairment writedown slowmove excess raw material work process inventory change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability net cash provide operating activity invest activity purchase marketable debt security proceed sale marketable debt security proceed maturitie marketable debt security acquisition include inprocess research development net cash acquire purchase equity security capital expenditure net cash investing activity financing activity proceed debt finance net issuance cost proceed issuance common stock repurchase common stock repayment debt obligation payment dividend net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead biopharmaceutical company pursue achieve breakthrough medicine decade goal create healthy world people commit advance innovative medicine prevent treat lifethreatening disease include hiv viral hepatitis cancer operate country worldwide headquarters foster city california portfolio market product include ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approve united states sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie material vie december certain reclassification prior period consolidated financial statement accompany note conform current presentation begin acquire inprocess research development iprd expense report separately research development expense consolidate statement income consolidate statement income year end december conform separately present acquire iprd expense segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need chief executive officer chief operating decisionmaker codm manage allocate resource operation company entitywide basis manage allocate resource entitywide basis enable codm assess overall level resource available well deploy resource function research development rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity good support longterm growth business note revenue summary disaggregate revenue product geographic region significant accounting policy estimate judgment preparation consolidate financial statement accordance generally accept accounting principle require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience marketspecific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source estimate assess period update reflect current information economic consideration relate impact coronavirus disease covid significant accounting estimate actual result differ significantly estimate revenue recognition product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party revenue recognize net estimate government rebate chargeback cash discount prompt payment distributor fee sale return provision relate deduction deduction product sale refer grossto net deduction estimate record period relate product sale occur payment term customer generally range day payment term differ jurisdiction customer instance type product revenue product sale net grosstonet deduction record extent significant reversal cumulative revenue recognize probable occurring uncertainty associate grosstonet deduction subsequently resolve taxis assess governmental authority collect customer exclude product sale expect contract inception period transfer control correspond payment customer year adjust consideration effect finance component grosstonet deduction rebate chargeback government rebate chargeback include amount payable payer healthcare provider program vary product payer individual payer plan rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price rebate chargeback estimate primarily base product sale expect payer mix discount rate require significant estimate judgment additionally develop estimate consider historical estimate payer mix statutory discount requirement contractual term historical claim experience processing time lag estimate patient population know market event trend market research channel inventory datum obtain major wholesaler pertinent internal external information assess update estimate report period reflect actual claim current information government chargeback payable direct customer generally classify reduction account receivable consolidated balance sheet government rebate payable party payer healthcare provider record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical customer payment pattern expectation future customer payment pattern distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale allowance sale return allowance estimate sale return customer record period relate revenue recognize typically permit return product damage defective customer united states typically permit return month prior year product expiration date outside united states return allow certain country limit basis estimate sale return base primarily analysis historical product return pattern industry information report return rate similar product contractual agreement term consideration know expect change marketplace specific product shipping handle shipping handling activity consider fulfillment activity consider separate performance obligation royalty contract revenue royalty revenue recognize period obligation satisfied correspond sale corporate partner occur research development expense rd expense consist primarily clinical study perform contract research organization cro material supply payment collaborative arrangement include milestone payment license fee expense reimbursement collaboration partner personnel cost include salary benefit stockbase compensation expense overhead allocation consist support infrastructure cost milestone payment thirdparty collaborator expense incur point regulatory approval milestone payment regulatory approval capitalize amortize remain useful life relate product time time enter development collaboration agreement share expense collaborative partner record payment receive collaborative partner share development cost reduction rd expense charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination payment rd service prior service render record prepay asset consolidate balance sheet expense service provide acquire inprocess research development expense acquire iprd expense reflect iprd impairment initial cost externally develop iprd project acquire directly transaction business combination alternative future use include upfront payment relate collaboration initial cost right iprd project acquire iprd expense acquisition date future cost develop iprd project record research development expense consolidate statement income incur sell general administrative expense sell general administrative sga expense relate sale marketing finance human resource legal administrative activity sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale expense cost advertising include promotional expense incur advertising expense million million million year end december respectively cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent marketable nonmarketable security marketable debt security determine appropriate classification marketable debt security time purchase reevaluate designation balance sheet date marketable debt security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable debt security longterm marketable debt security unrealize gain loss availableforsale debt security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest amortization purchase premium discount realize gain loss sale security expect credit loss cost security sell base specific identification method regularly review investment decline fair value amortize cost basis determine impairment creditrelate factor noncreditrelate factor review include creditworthiness security issuer severity unrealized loss intent sell security likely require sell security recovery amortize cost basis determine portion unrealize loss expect credit loss recognize loss income expense net correspond allowance carry value security hold portion unrealize loss relate factor credit loss recognize aoci marketable nonmarketable equity security investment equity security equity method investment record fair market value fair value readily determinable unrealized gain loss include income expense net consolidated statement income investment entity significant influence meet requirement consolidation elect fair value option use equity method accounting share underlie income loss entity report income expense net consolidated statement income elect fair value option account equity investment arcus biosciences inc arcus galapagos nv galapagos significant influence believe fair value option well reflect underlie economic investment note collaboration arrangement additional information equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer certain investment equity security nonpublic company account equity method base ownership percentage factor indicate significant influence investee note collaboration arrangement additional information investment equity securities record prepay current asset longterm asset consolidate balance sheet regularly review security indicator impairment concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment credit loss estimate allowance credit loss consider number factor include exist contractual payment term individual customer circumstance historical payment pattern customer review local economic environment potential impact expect future customer payment pattern government funding reimbursement practice majority trade account receivable arise product sale united states europe addition allowance credit loss writeoff recovery customer receivables material year end december inventory inventory record low cost net realizable value cost determine firstin firstout basis periodically review inventory identify obsolete slowmove excess unsaleable item obsolete slowmove excess unsaleable item observe alternate use inventory record writedown net realizable value charge cost good sell consolidated statement income determination net realizable value require judgment include consideration factor estimate future product demand product net selling price current future market condition potential product obsolescence future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor consider include current status regulatory approval process potential impediment approval process safety efficacy anticipate rd initiative impact indication compound viability commercialization marketplace trend property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement short year useful life laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term lease determine arrangement contain lease inception rightofuse asset lease liability recognize commencement date base present value lease payment lease term noncancelable period state contract adjust option extend terminate reasonably certain exercise option rightofuse asset adjust prepay lease payment lease incentive initial direct cost incur operating lease expense minimum lease payment recognize straightline basis lease term account lease nonlease component lease agreement single lease component determine lease asset liability addition recognize rightofuse asset liability lease lease term year operating lease provide implicit interest rate generally utilize collateralized incremental borrowing rate apply portfolio approach relevant base information available commencement date determine lease liability acquisition account business combination acquisition method accounting generally require asset acquire include iprd project liability assume record fair value acquisition date consolidate balance sheet excess consideration fair value net asset acquire record goodwill determination estimate fair value require significant estimate assumption result record adjustment fair value asset acquire liability assume measurement period year acquisition date correspond offset goodwill transaction cost associate business combination expense incur determine net asset acquire meet definition business combination acquisition method accounting transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date subsequent milestone payment expense incur consolidated statement income alternative future use goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset measure respective fair value acquisition date subject adjustment measurement period year acquisition date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort amortize goodwill intangible asset indefinite useful life goodwill indefinitelive intangible asset test impairment annually frequently event change circumstance indicate likely asset impair development successfully complete generally occur regulatory approval obtain associate asset deem finitelived amortize respective estimate useful life begin point time intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance indicate carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally indicate carry value asset recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset carrying asset asset group asset asset group determine impair excess carrying value asset asset group estimate fair value recognize impairment loss valuation contingent consideration result business combination connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event record contingent consideration result business combination fair value acquisition date report period revalue obligation record increase decrease fair value research development expense consolidate statement income time relate product candidate receive marketing approval increase decrease fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss material year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose fair value financial instrument apply fair value account financial nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet unrealize change fair value derivative designate hedge transaction record aoci unrealize gain loss aoci reclassify product sale consolidate statement income respective hedge transaction affect earning change fair value derivative hedge transaction record period income expense net consolidated statement income assess inception ongoing basis derivative hedging transaction effective offset change cash flow fair value hedge item determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income sharebase compensation provide sharebased compensation form type equitybase award include restrict stock unit rsus performance share award unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant stock option award estimate fair value base blackschole option valuation model contingency party legal action recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine material loss reasonably possible disclose possible loss range loss loss estimate time income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation applicable tax law regulation recognize tax benefit uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize consolidated financial statement particular tax position base large benefit likely realize unrecognized tax benefit utb adjust appropriate change fact circumstance significant amendment exist tax law new regulation interpretation tax authority new information obtain tax examination resolution examination recognize accrue interest penalty appropriate relate utb income tax expense benefit consolidate statement income elect account tax global intangible lowtaxed income enact tax cut job act component tax expense period tax incur significant accounting policy significant accounting policy describe remain appropriate note consolidated financial statement revenue disaggregation revenue revenue follow year end december year end december year end december million europe international total europe international total europe international total product sale hiv atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada revenue share symtuza hiv total hiv veklury hepatitis c virus hcv ledipasvir sofosbuvir sofosbuvirvelpatasvir hcv total hcv hepatitis b virus hbv hepatitis delta virus hdv vemlidy viread hbvhdv total hbvhdv cell therapy tecartus yescarta total cell therapy trodelvy ambisome letairis ranexa zydelig total total product sale royalty contract revenue total revenue represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland unlimited company janssen include emtriva tybost amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include vosevi sovaldi include hepcludex hepsera include cayston jyseleca revenue major customer follow table summarize revenue customer individually account total revenue year end december percentage total revenue amerisourcebergen corporation cardinal health inc mckesson corporation revenue recognize performance obligation satisfy prior period revenue recognize performance obligation satisfy prior year relate revenue share janssen describe note collaboration arrangement royalty license intellectual property million million million year end december respectively revenue product sale net grosstonet deduction record extent significant reversal cumulative revenue recognize probable occurring uncertainty associate grosstonet deduction subsequently resolve estimate assess period update reflect current information change estimate related sale prior year result million million million increase revenue year end december respectively primarily relate change estimate accrue government rebate allowance sale return product expiration contract balance contract asset consist unbilled amount primarily arrangement license intellectual property predominant performance obligation total million million december respectively contract liability generally result receipt advance payment performance contract material december respectively revenue expect recognize future contract liability relate performance obligation satisfy expect material year fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable debt security certain equity security foreign currency exchange contract report respective fair value consolidate balance sheet equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value transfer level level level period present follow table summarize type asset liability measure fair value recur basis level fair value hierarchy december december millions level level level total level level level total asset availableforsale debt security treasury security government agency security nonus government security certificate deposit corporate debt security residential mortgage assetbacke security equity security money market fund equity investment galapagos equity investment arcus publicly trade equity security defer compensation plan foreign currency derivative contract total liability liability myr gmbh myr contingent consideration defer compensation plan foreign currency derivative contract total note collaboration arrangement additional information equity security follow table summarize classification equity security measure fair value recur basis consolidated balance sheet million december december cash cash equivalent prepay current asset longterm asset total change fair value equity security result net unrealized loss million billion net unrealized gain billion year end december respectively include income expense net consolidated statement income equity security equity method investment equity investment readily determinable fair value million million december respectively exclude table amount include longterm asset consolidate balance sheet relate party transaction second quarter donate certain equity security fair value gilead foundation california nonprofit organization foundation foundation relate party certain officer company serve director foundation donation expense million record sell general administrative expense consolidate statement income year end december level input estimate fair value level investment take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include incomebase marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent sp global rating moodys investors service inc fitch ratings inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate libor swap rate input applicable observable commonly quote interval total estimate fair value aggregate shortterm longterm debt determine level input base quote market value approximately billion billion december respectively carry value billion billion december respectively level input connection quarter acquisition myr measure asset acquire liability assume fair value nonrecurre basis liability contingent consideration estimate fair value liability contingent consideration million million acquisition date december respectively change estimate fair value acquisition date primarily effect foreign exchange remeasurement contingent consideration estimate probabilityweighte scenario food drug administration fda approval hepcludex note acquisition additional information connection fourth quarter acquisition immunomedics inc immunomedics measure asset acquire liability assume fair value nonrecurre basis liability assume related sale future royalty subsequently amortize effective interest method remain estimate life fair value liability relate sale future royaltie billion billion december respectively carry value billion december note acquisition note debt credit facility additional information connection collaboration equity arrangement enter pionyr immunotherapeutics inc pionyr tizona therapeutics inc tizona measure fair value exclusive option acquire remain outstanding capital stock pionyr tizona nonrecurre basis note collaboration arrangement additional information measure iprd intangible asset acquire connection acquisition kite pharma inc kite fair value nonrecurre basis recognize pretax impairment charge million fair value acquire iprd asset estimate base probabilityadjuste discount cash flow calculation level fair value measurement input include estimate revenue cost probability technical regulatory success discount rate amount capitalize iprd subject impairment testing completion abandonment associate rd effort note goodwill intangible asset additional information policy recognize transfer level classification actual date event change circumstance cause transfer transfer level level level period present availableforsale debt security follow table summarize availableforsale debt security december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate million cost gain loss fair value cost gain loss fair value treasury security government agency security nonus government security certificate deposit corporate debt security residential mortgage assetbacke security total follow table summarize classification availableforsale debt security consolidate balance sheet million december december cash cash equivalent shortterm marketable debt security longterm marketable debt security total follow table summarize availableforsale debt security contractual maturity december millions amortize cost fair value year year year year total hold total position unrealize loss position december respectively aggregate gross unrealized loss availableforsale debt security material year end december impairment recognize year end december derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency primarily euro manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity month execute hedging contract reporting period assess hedge effectiveness regression analysis unrealize gain loss aoci reclassify product sale consolidate statement income respective hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion billion december respectively derivative contract allow right offset asset liability present amount gross basis follow table summarize classification fair value derivative instrument consolidate balance sheet december derivative asset derivative liability fair fair million classification value classification value derivative designate hedge foreign currency exchange contract prepay current asset accrue current liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract prepay current asset accrue current liability total derivative designate hedge total derivative december derivative asset derivative liability fair fair million classification value classification value derivative designate hedge foreign currency exchange contract prepay current asset accrue current liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract prepay current asset accrue current liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement year end december million derivative designate hedge gain loss recognize aoci gain loss reclassify aoci product sale derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income discontinuance cash flow hedge year present december hold foreign currency exchange contract follow table summarize potential effect offset foreign currency exchange contract consolidate balance sheet gross amount offset consolidated balance sheet amount gross amount assetsliabilitie gross amount offset present derivative recognize consolidated balance consolidate balance financial cash collateral net million assetsliabilitie sheet sheet instrument receivedpledge legal offset december derivative asset derivative liability december derivative asset derivative liability acquisition myr quarter complete acquisition myr german biotechnology company myr focus development commercialization therapeutic treatment hdv acquisition provide gilead hepcludex conditionally approve european medicine agency ema july treatment chronic hdv infection adult compensate liver disease closing myr whollyowne subsidiary gilead financial result myr include consolidated financial statement date acquisition acquisitionrelated expense material year end december aggregate consideration acquisition billion billion primarily consist billion billion pay close contingent consideration million subject customary adjustment represent potential future milestone payment fda approval hepcludex fair value contingent liability estimate probabilityweighte scenario fda approval million acquisition date initially record longterm obligation consolidate balance sheet second quarter balance reclassify accrued current liability consolidated balance sheet estimate fair value contingent liability million december change estimate fair value acquisition date primarily effect foreign exchange remeasurement acquisition myr account business combination acquisition method accounting method require thing asset acquire liability assume generally recognize fair value acquisition date fair value estimate asset acquire liability assume base valuation information know knowable date filing change assumption estimate cause impact valuation asset acquire include intangible asset goodwill relate tax impact acquisition legal contingency amount recognize finalized information necessary complete analysis obtain later year acquisition date follow table summarize estimate fair value asset acquire liability assume acquisition date million intangible asset finitelive intangible asset acquire iprd defer income taxis net asset liability net total identifiable net asset goodwill total consideration intangible asset finitelive intangible asset million represents estimate fair value hepcludex hdv europe acquisition date fair value determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable hepcludex hdv europe discount rate discount rate represent estimate rate market participant use value intangible asset intangible asset amortize estimate useful life year acquire iprd consist hepcludex hdv region regulatory approval include united states estimate aggregate fair value billion acquisition date determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable asset discount rate discount rate represent estimate rate market participant use value intangible asset significant assumption inherent development intangible asset fair value include estimate project future cash flow include revenue operate profit probability success discount rate select life potential commercialize product risk related viability potential alternative treatment future target market factor input value identifiable intangible unobservable consider level fair value measurement disclosure guidance note fair value measurement additional information defer income taxis net defer tax liability base difference estimate financial statement basis tax basis net asset acquire estimate final preacquisition net operating loss myr goodwill excess consideration transfer fair value asset acquire liability assume million record goodwill primarily reflect future economic benefit arise asset acquire individually identify separately recognize goodwill recognize myr expect deductible income tax purpose material measurement period adjustment record fair value asset acquire liability assume year end december immunomedic fourth quarter complete acquisition immunomedics company focus development antibodydrug conjugate technology cash consideration billion closing immunomedic whollyowne subsidiary gilead acquisition finance majority proceed september senior unsecured note offer additional billion borrow new senior unsecured term loan facility cash hand repay borrow senior unsecured term loan facility note debt credit facility additional information record sharebased compensation expense million relate cash settlement accelerate sharebased compensation expense attributable postcombination period primarily record sell general administrative expense research development expense consolidate statement income year end december record acquisitionrelate expense million primarily represent closing cost relate fee sell general administrative expense consolidate statement income year end december acquisition immunomedic account business combination acquisition method accounting method require thing asset acquire liability assume generally recognize fair value acquisition date material measurement period adjustment record fair value asset acquire liability assume year end december fair value estimate asset acquire liability assume complete follow table summarize fair value asset acquire liability assume acquisition date million cash cash equivalent inventory intangible asset finitelive intangible asset acquire iprd outlicense contract defer tax liability liability relate future royalty asset liability net total identifiable net asset goodwill total consideration transfer inventory fair value stepup adjustment million include inventory million acquisition date primarily determine estimate selling price finish inventory cost complete manufacturing process sell effort stepup adjustment record cost good sell consolidated statement income inventory sell customer research development expense consolidate statement income inventory clinical purpose intangible asset finitelive intangible asset billion represents estimate fair value trodelvy metastatic triplenegative breast cancer tnbc acquisition date fair value determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable trodelvy metastatic tnbc discount rate discount rate represent estimate rate market participant use value intangible asset intangible asset amortize estimate useful life year acquire iprd asset consist trodelvy hormone receptor positive human epidermal growth factor receptor negative metastatic breast cancer trodelvy nonsmall cell lung cancer trodelvy urothelial cancer uc estimate aggregate fair value billion acquisition date determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable asset discount rate discount rate represent estimate rate market participant use value intangible asset trodelvy uc grant accelerated approval fda april billion reclassify finitelived intangible iprd note goodwill intangible asset additional information significant assumption inherent development intangible asset fair value include timing project future cash flow include revenue cost sale research development cost sale marketing expense probability success discount rate select measure inherent risk future cash flow assessment asset life cycle competitive trend impact asset factor record intangible asset relate license supply agreement party enter immunomedic prior acquisition agreement party grant exclusive license develop commercialize trodelvy certain territory asia certain sale milestone royalty payment acquisition date fair value million determine estimate probabilityweighte net cash flow attributable outlicense discount rate discount rate represent estimate rate market participant use value intangible asset intangible asset amortize estimate useful life year straightline basis input value identifiable intangible unobservable consider level fair value measurement disclosure guidance defer income taxis net defer tax liability base difference estimate financial statement basis tax basis net asset acquire estimate final preacquisition net operating loss immunomedics liability relate future royalty assume liability relate funding arrangement originally enter immunomedics rpi finance trust rpi prior acquisition immunomedic funding agreement rpi right receive certain royalty amount subject certain reduction base net sale trodelvy calendar quarter term agreement approximately acquisition date fair value liability estimate billion primarily determine base current estimate future royalty payment rpi life arrangement real option method effective annual interest rate liability amortize effective interest rate method result recognition interest expense year estimate timing future expect royalty payment estimate term reassess reporting period impact change estimate recognize liability relate interest expense prospectively input valuation liability unobservable consider level fair value measurement disclosure guidance note fair value measurement additional information liability relate future royalty categorize debt primarily include longterm debt net consolidated balance sheet note debt credit facility additional information goodwill excess consideration transfer fair value asset acquire liability assume billion record goodwill primarily reflect future economic benefit arise asset acquire individually identify separately recognize goodwill recognize immunomedic expect deductible income tax purpose seven inc seven second quarter complete acquisition seven clinicalstage immunooncology company focus develop therapy target cancer immune evasion pathway specific cell target approach total consideration billion net acquire cash close seven whollyowne subsidiary gilead account transaction asset acquisition lead asset magrolimab represent substantially fair value gross asset acquire year end december record billion charge represent acquire iprd asset alternative future use acquire inprocess research development expense stockbase compensation expense million primarily research development expense consolidate statement income inventory follow table summarize inventory december million raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december total inventory december include million million respectively fair value adjustment result immunomedics acquisition inventory writedown charge million million million year end december respectively year end december million million inventory writedown charge related slowmove excess raw material work process inventory primarily low longterm demand hcv product property plant equipment follow table summarize property plant equipment net december million land land improvement building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total unamortized capitalize software cost include office computer equipment million million december respectively capitalize interest construction progress include property plant equipment net consolidated balance sheet interest capitalize material net book value property plant equipment united states billion billion december respectively correspond international location million million december respectively individual international location account total balance goodwill intangible asset goodwill follow table summarize change carry goodwill december millions begin balance goodwill result acquisition measurement period adjustment end balance perform annual goodwill impairment assessment fourth quarter early impairment indicator exist december accumulate goodwill impairment loss intangible asset follow table summarize intangible asset net december december gross foreign currency gross foreign currency carry accumulate translation net carry carry accumulate translation net carry million amortization adjustment amortization adjustment finitelive asset intangible asset sofosbuvir intangible asset axicabtagene ciloleucel intangible asset trodelvy intangible asset hepcludex total finitelived asset indefinitelive asset iprd total intangible asset gross carrying december include million reclassify quarter indefinitelive asset iprd follow march fda approval yescarta treatment adult patient relapse refractory follicular lymphoma gross carrying december include trodelvy metastatic tnbc trodelvy use adult patient locally advance metastatic uc relate uc billion reclassify finitelived asset indefinitelive asset iprd accelerate approval fda april october fda grant approval tecartus treatment adult patient relapse refractory bcell precursor acute lymphoblastic leukemia accordingly relate million reclassify finitelived asset fourth quarter gross carrying december include iprd acquisition myr remain iprd acquisition immunomedics gross carrying december include iprd acquisition immunomedics remain iprd acquisition kite aggregate amortization expense relate finitelive intangible asset billion billion billion year end december respectively primarily include cost good sell consolidated statement income amount capitalize iprd subject impairment testing completion abandonment associate rd effort perform qualitative assessment iprd intangible asset obtain connection quarter acquisition myr identify indicator impairment perform quantitative impairment testing iprd intangible asset myr asset describe probabilityweighte income approach discount expect future cash flow present value discount rate respectively discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use level fair value measurement input include estimate revenue cost probability technical regulatory success iprd impairment charge record lower estimate revenue relate iprd intangible asset axicabtagene ciloleucel treatment indolent bcell nonhodgkin lymphoma change estimate market opportunity new therapy combination exist therapy approve low estimate revenue reduce fair value iprd intangible asset carry value result recognition impairment charge million record acquire inprocess research development expense consolidate statement income follow table summarize estimate future amortization expense associate finitelive intangible asset december million total financial information account receivable net follow table summarize account receivable net december millions account receivable chargeback cash discount allowance credit loss account receivable net accrue current liability follow table summarize component accrue current liability december millions compensation employee benefit income taxis payable allowance sale return accrual settlement relate bictegravir litigation accrue liability accrue current liability note commitment contingency additional information collaboration arrangement enter license strategic collaboration similar arrangement party development commercialization certain product product candidate arrangement involve party active participant operating activity collaboration expose significant risk reward depend commercial success activity arrangement include nonrefundable upfront payment expense reimbursement payment option acquire certain right contingent obligation potential development regulatory milestone payment andor salesbase milestone payment royalty payment revenue profitshare arrangement costshare arrangement equity investment party focus development commercialization product product candidate merck co inc merck march enter license collaboration agreement merck sharp dohme corp subsidiary merck jointly develop commercialize longacte investigational treatment hiv combine gilead investigational capsid inhibitor lenacapavir merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir collaboration initially focus longacte oral injectable formulation term agreement gilead merck share global development commercialization cost respectively oral injectable formulation program longacte oral product approve gilead lead commercialization united states merck lead commercialization european union eu rest world longacte injectable product approve merck lead commercialization united states gilead lead commercialization eu rest world term agreement gilead merck jointly promote combination product united states certain major market successful share global product revenue merck equally product revenue surpass certain predetermine formulation revenue tier pass billion net product sale oral combination give calendar year share revenue increase revenue threshold calendar year pass billion net product sale injectable combination give calendar year share revenue increase revenue threshold calendar year reimbursement research development cost merck record research development expense consolidate statement income expense recognize agreement material year end december revenue recognize agreement year end december option license certain merck investigational oral integrase inhibitor develop combination lenacapavir reciprocally merck option license certain gilead investigational oral integrase inhibitor develop combination islatravir company exercise option investigational oral integrase inhibitor company year execution agreement follow completion phase clinical trial integrase inhibitor exercise option company split development cost revenue nonexercise company decide optout case nonexercise company pay royalty december merck announce decision party stop dose participant phase clinical study evaluate oralweekly combination treatment regimen lenacapavir islatravir follow decision fda place clinical hold investigational new drug application certain formulation islatravir arcus enter transaction arcus publicly trade oncologyfocused biopharmaceutical company include entry option license collaboration agreement collaboration agreement common stock purchase agreement investor right agreement subsequently amend stock purchase agreement accordance term collaboration agreement stock purchase agreement close july upfront payment million acquire approximately million share arcus common stock approximately million total million initial cash payment include transactional cost agreement record million equity investment calculate base arcus close stock price closing date transaction remain million attribute acquire license option right million represent iprd asset alternative future use ii million issuance premium equity purchase iii million direct transactional cost amount expense acquire inprocess research development expense year end december consolidate statement income stock purchase agreement right purchase additional share arcus arcus fiveyear period begin close stock purchase agreement maximum outstanding voting stock subject threeyear standstill restricting ability acquire voting stock arcus exceed thenissue outstanding voting stock arcus subject certain exception additionally agree dispose equity security arcus prior second anniversary closing stock purchase agreement prior consent arcus subject certain exception separate secondary equity offering acquire million share common stock arcus approximately million quarter acquire approximately million additional share arcus common stock million result currently total million share arcus represent approximately issue outstanding voting stock arcus immediately follow close quarter transaction pursuant collaboration agreement gilead right opt current future clinicalstage product candidate year follow closing transaction november exercise option arcus clinical stage program amend collaboration agreement option exercise amendment transaction close december trigger collaboration optin payment million waive million option continuation payment arcus quarter net option charge million record research development expense consolidate statement income year end december collaboration optin payment million record accrue current liability consolidated balance sheet december pay arcus january payment arcus include net cash provide investing activity consolidate statement cash flow quarter amend collaboration agreement company codevelop share global cost relate clinical program optione molecule achieve regulatory approval company cocommercialize equally share profit gilead hold exclusive commercialization right outside subject right arcuss exist collaboration partner pay arcus tiere royalty percentage net sale range midteen low twenty collaboration agreement pay additional million option fourth sixth eighth anniversary agreement terminate early maintain right optin future arcus program duration contact term elect apply fair value option account equity investment arcus investment mark market reporting period base market price arcus share believe fair value option well reflect underlying economic investment year end december record pretax unrealize gain million million respectively relate investment arcus income expense net consolidated statement income initially record equity investment arcus longterm asset consolidate balance sheet investment subject contractual lockup provision period year closing date stock purchase agreement subject certain condition quarter reclassify equity investment arcus prepay current asset consolidate balance sheet contractual lockup provision expect expire july equity investment arcus million million december respectively pionyr june enter transaction pionyr privately hold company pursue novel biology field immunooncology include entry separate merger agreement contemplate initial acquisition equity interest pionyr provide exclusive option subject certain term condition acquire remain outstanding capital stock pionyr pionyr merger option agreement research development service agreement july close transaction cash payment million account investment pionyr equity method accounting equity interest provide ability exercise significant influence pionyr investment pionyr consist transaction price note transaction cost exceed prorata portion pionyr net asset transaction closing determine result basis difference primarily relate pionyr iprd alternative future use pionyr business define asc business combination result immediately record charge basis difference million acquire inprocess research development expense consolidate statement income year end december carry value equity method investment pionyr zero december estimate fair value exclusive option acquire remain outstanding capital stock pionyr approximately million base probability weight option pricing model unobservable input consider level fair value measurement disclosure guidance estimate record longterm asset consolidate balance sheet choose exercise exclusive option purchase remain equity interest pionyr current shareholder million option exercise fee billion potential future milestone payment achievement certain development regulatory milestone option purchase expire follow early occurrence specify event include delivery datum follow completion certain phase b trial pionyr research development service agreement initial cash funding million record charge acquire inprocess research development expense consolidate statement income year end december addition commit provide additional payment million pionyr achievement certain development milestone accrue million milestone payment relate initiation phase study charge research development expense consolidate statement income year end december payment quarter tizona july enter transaction tizona privately hold company develop cancer immunotherapy include entry separate merger agreement contemplate initial acquisition equity interest tizona provide exclusive option subject certain term condition acquire remain outstanding capital stock tizona tizona merger option agreement development agreement august close transaction tizona cash payment million tizona shareholder accordance term tizona merger option agreement account investment tizona equity method accounting equity interest provide ability exercise significant influence tizona investment tizona consist transaction price note transaction cost exceed prorata portion tizona net asset transaction closing determine result basis difference primarily relate tizonas iprd alternative future use tizona business define asc business combination result year end december immediately record charge basis difference million acquire inprocess research development expense consolidate statement income carry value equity method investment tizona zero december estimate fair value exclusive option acquire remain outstanding capital stock tizona approximately million base probability weight option pricing model unobservable input consider level fair value measurement disclosure guidance estimate record longterm asset consolidate balance sheet choose exercise exclusive option purchase remain equity interest tizona current shareholder million option exercise fee billion potential future milestone payment achievement certain development regulatory milestone option purchase expire follow early occurrence specify event include delivery datum follow completion certain phase b trial tizona development agreement commit provide fund tizona million record acquire inprocess research development expense consolidate statement income year end december tango therapeutics inc tango august enter transaction tango privately hold company pursue innovative target immune evasion therapie patient cancer proprietary crisprenable functional genomic target discovery platform include entry amend restate research collaboration license agreement stock purchase agreement tango collaboration stock purchase agreement enter transaction upfront payment million million equity investment tango year end december record million upfront expense acquire inprocess research development expense consolidate statement income quarter additional million equity investment tango publicly trade company quarter accordingly equity investment record prepay current asset consolidate balance sheet fair market value december tango collaboration stock purchase agreement gilead right option program sevenyear collaboration million program optin extension milestone payment product tango opt codevelop copromote party equally split profit loss development cost products tango opt codevelop copromote pay tango low doubledigit tiere royalty net sale provide tango milestone payment royaltie sale outside jounce therapeutics inc jounce september enter transaction jounce publicly trade company develop novel cancer immunotherapy include entry license registration right stock purchase agreement jounce license stock purchase agreement october close transaction total payment million record million upfront expense acquire inprocess research development expense consolidate statement income million equity investment longterm asset consolidate balance sheet represent approximately issue outstanding voting stock jounce immediately follow transaction calculate base jounce close stock price closing date transaction december jounce eligible receive million future potential clinical regulatory commercial milestone payment achievement certain milestone royalty range high single digit midteen base worldwide sale subject certain adjustment galapagos filgotinib collaboration close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication filgotinib agreement closing upfront license fee payment equity investment galapago subscribe million new ordinary share galapagos price share amend term agreement term filgotinib agreement amend agreement obtain exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib december follow type meeting fda discuss point raise complete response letter relate new drug application filgotinib treatment rheumatoid arthritis gilead galapagos agree amend agreement allow galapago assume development manufacturing commercialization certain right filgotinib europe party reflect amendment agreement december beginning january galapagos bore development cost certain study lieu equal cost split contemplated agreement party transfer filgotinibs marketing authorization eu great britain galapagos december january commercial economics filgotinib europe transfer galapagos subject payment tiere royalty net sales europe gilead start connection amendment agreement gilead agreed irrevocably pay galapagos million approximately million subject certain adjustment higherthanbudgete development cost total gilead pay million approximately million january pay additional million approximately million april pay million approximately million accrue liability charge research development expense consolidate statement income year end december addition galapagos long eligible receive future milestone payment relate filgotinib europe global collaboration august close option license collaboration agreement galapago collaboration agreement subscription agreement galapagos subscription agreement galapago pursuant party enter global collaboration cover galapago current future product portfolio filgotinib closing pay billion license option right million new ordinary share galapagos subscription price share fair value billion include issuance discount million calculate base galapago close stock price date closing galapago subscription agreement remain billion payment record acquire inprocess research development expense consolidate statement income year end december pursuant galapagos subscription agreement issue warrant confer right subscribe time time number new share issue galapagos sufficient bring number share own issue outstanding share time exercise exercise warrant subscribe million ordinary share galapago share purchase share open market aggregate fair value million bring number share own million approximately share issue outstanding subject year standstill restrict ability acquire voting security galapago exceed thenissue outstanding voting security galapago agree prior consent galapago dispose equity security galapago prior second anniversary closing galapago subscription agreement dispose equity security galapago fifth anniversary closing galapago subscription agreement disposal thenissue outstanding voting security galapago subject certain exception termination event april amend galapagos subscription agreement extend initial lockup provision certain galapago share august august designee appoint galapago board director initial contractual lockup provision certain galapagos share expire august million include prepaid current asset consolidate balance sheet remainder billion include longterm asset consolidate balance sheet december subsequent extension contractual lockup period equity investment galapago classify long term asset consolidate balance sheet million december elect fair value option account equity investment galapago investment mark market earning reporting period base market price galapago share believe fair value option well reflect underlying economic investment year end december record pretax unrealize loss million billion pretax unrealized gain billion respectively relate investment galapago income expense net consolidated statement income change galapagos stock price galapago collaboration agreement exclusive license development commercialization glpg latestage candidate idiopathic pulmonary fibrosis territory option participate development commercialization galapago current future clinical program enter clinical development year collaboration subject extension certain circumstance gilead galapago terminate phase clinical study glpg february respect program galapagos current future pipeline exercise option program pay million option exercise fee program addition galapago receive tiere royalty range net sale territory galapago product optione exercise option program party share equally development cost mutually agree commercialization cost incur subsequent exercise option terminate collaboration entirety programbyprogram countrybycountry basis advance notice follow customary termination event janssen compleraeviplera odefsey enter license collaboration agreement janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve eu sell brand complera eviplera eu agreement amend expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product certain country outside party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country sell party financial provision amendment sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue include major market sale product include product sale janssen share revenue include cost good sell consolidated statement income cost good sell relate janssen share million million million year end december respectively termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term terminate agreement cause respect country sell product case janssen right sell party country product launch market few year symtuza amend license collaboration agreement janssen develop commercialize fixeddose combination janssen darunavir cobicistat emtricitabine tenofovir alafenamide gilead compound combination approve eu july september respectively sell brand symtuza term amendment grant janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property relate gilead compound exclusive supplier gilead compound party restrict combine drug drug product similar component symtuza janssen set price symtuza party share revenue base ratio net selling price party component subject certain restriction adjustment intellectual property license supply obligation relate gilead compound account single performance obligation license deem predominant item revenue share relate recognize share symtuza revenue period correspond sale symtuza janssen occur record share symtuza revenue product sale consolidate statement income primarily supply gilead compound janssen symtuza termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term janssen terminate agreement cause countrybycountry basis case gilead right sell party countryie product launch market few year janssen terminate entire agreement cause japan tobacco inc japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right effective december enter agreement japan tobacco acquire right market distribute certain product hiv portfolio japan expand right develop commercialize elvitegravir include japan responsible marketing product january responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort pay royalty japan tobacco base product sale sale product include product sale consolidate statement income royalty japan tobacco include cost good sell consolidated statement income royalty expense recognize million million million year end december respectively term agreement pay japan tobacco million cash recognize intangible asset million reflect estimate fair value marketingrelate right acquire japan tobacco intangible asset amortize year represent period majority benefit expect derive applicable product hiv portfolio amortization expense classify selling expense record sell general administrative expense consolidate statement income termination agreement product country basis depend circumstance include material breach party expiry royalty payment term terminate entire agreement cause gadeta bv gadeta july enter collaboration arrangement gadeta purchase equity gadeta gadeta shareholder determine gadeta vie primary beneficiary power direct activity gadeta significantly impact economic performance initial consolidation gadeta record million noncontrolle interest primarily reflect acquire intangible asset relate iprd consolidated balance sheet year end december effectively terminate agreement gadeta effective termination cease control interest deconsolidate vie remove related net asset noncontrolle interest million consolidated balance sheet net loss deconsolidation material collaboration arrangement individually significant enter collaboration equity investment license arrangement similar arrangement consider individually material record upfront collaboration expense relate arrangement million million million year end december respectively acquire inprocess research development expense consolidate statement income cash payment equity investment note year end december million million million respectively primarily record prepaid current asset longterm asset consolidate balance sheet financial term arrangement require payment achievement developmental regulatory commercial milestone significant future milestone payment reflect consolidated statement income correspond event probable connection regulatory approval milestone payment capitalize intangible asset amortize cost good sell term collaboration arrangement addition require pay significant royalty future sale product relate arrangement commercialize payment amount contingent occurrence future event high degree uncertainty debt credit facility follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate senior unsecured march april senior unsecured september september month libor senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured september september month libor senior unsecured september september term loan october october variable senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october total senior unsecured note term loan facility liability relate future royalty total debt net current portion longterm debt obligation net total longterm debt net senior unsecured note term loan facility repay billion debt consist billion senior unsecured note billion senior unsecured term loan facility repay billion senior unsecured note april quarter billion senior unsecured note december quarter additionally repay million senior unsecured float rate note maturity september october exercise option million senior unsecured float rate note million senior unsecured note final maturity date september early repayment total billion principal fourth quarter december exercise option million senior unsecured note final maturity march note repay february new debt issue senior unsecured fix rate note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior unsecured fix rate note feature exercisable option redeem note par date range month year prior maturity case accrue unpaid interest require redeem date redemption billion senior unsecured note september feature exercisable option redeem note par september event occurrence change control downgrade rate senior unsecured note investment grade moodys investors service inc sp global rating holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant note indenture govern senior unsecured note december violation covenant september enter commitment letter group institutional lender provide threeyear senior unsecured term loan facility aggregate principal billion october connection acquisition immunomedic enter term loan credit agreement term loan facility borrow aggregate principal billion repay billion principal outstanding term loan facility maturity october liability relate future royalty connection acquisition immunomedic assume liability relate funding arrangement originally enter immunomedic rpi prior acquisition immunomedic liability relate future royalty primarily include longterm debt net consolidated balance sheet note acquisition additional information revolve credit facility june terminate billion fiveyear revolve credit facility mature revolve credit facility enter new billion fiveyear revolve credit facility mature june revolve credit facility revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding revolve credit facility revolve credit facility contain customary representation warranty affirmative negative covenant event default december compliance covenant loan revolve credit facility bear interest eurodollar rate plus applicable percentage ii base rate plus applicable percentage define revolve credit facility agreement terminate reduce commitment prepay loan credit facility time premium penalty contractual maturity finance obligation follow table summarize aggregate future principal maturity senior unsecured note december million total interest expense interest expense debt credit facility relate contractual coupon rate amortization debt discount issuance cost billion lease operating lease consist primarily property equipment administrative manufacturing rd activity lease include option extend term year include option terminate lease year lease commencement date december material finance lease operate lease expense include variable cost shortterm lease million million million respectively follow table summarize balance sheet information relate operating lease december millions weight average amount classification rightofuse asset net longterm asset lease liability current accrue current liability lease liability noncurrent longterm obligation weight average remain lease term year year weight average discount rate follow table summarize supplemental information relate operating lease year end december million cash pay amount include measurement lease liability rightofuse asset obtain exchange lease liability follow table summarize maturity analysis operating lease liability show aggregate lease payment december million total undiscounted lease payment imputed interest total discount lease payment commitment contingency legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine material loss reasonably possible loss range loss estimate disclose possible loss note outcome matter expect material possible determine reasonably estimate maximum potential exposure range possible loss quarter reverse million previously record litigation accrual follow favorable court decision litigation relate axicabtagene ciloleucel describe fourth quarter record accrual billion accrue current liability consolidate balance sheet settlement relate bictegravir litigation describe litigation relate sofosbuvir acquire pharmasset inc acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv receive approval fda sofosbuvir know commercially sovaldi sofosbuvir include market hcv product receive number litigation claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir court grant motion transfer case california file petition inter parte review patent trademark office patent trial appeal board ptab allege assert claim invalid anticipation obviousness ptab institute petition merit hear hold february district court northern district california stay litigation ptab conclude inter partes review initiate ptab issue write decision finding assert claim universitys patent invalid july university appeal decision litigation district court remain stay appeal proceeding litigation nucana plc nucana nucana obtain european patent ep patent allegedly cover sofosbuvir opposition proceeding european patent office epo hold february epo opposition division uphold validity ep patent amend form believe amend ep patent claim invalid subsequently initiate proceeding invalidate uk counterpart ep patent high court england wale march nucana file counterclaim high court england wale allege patent infringement uk counterpart seek damage relief april nucana file lawsuit germany landgericht dsseldorf allege patent infringement german counterpart ep patent seek damage injunctive relief hearing date german nucana case schedule hear date uk nucana case schedule january litigation relate axicabtagene ciloleucel october juno therapeutics inc sloan kettere cancer center collectively juno file lawsuit district court central district california allege commercialization axicabtagene ciloleucel sell commercially yescarta infringe patent patent jury trial hold patent december jury find asserted claim patent valid willfully infringe assert claim patent jury award juno damage amount million upfront payment run royalty october date jurys verdict party file posttrial motion quarter trial judge enter judgment april trial judge affirm jurys verdict enhance past damage maintain royalty future yescarta sale april file appeal seek reverse judgment obtain new trial error trial judge july appeals court hear oral argument august court appeal federal circuit cafc reverse jury verdict finding assert claim juno patent invalid october juno file petition rehear cafc january cafc deny juno petition rehear believe likelihood material adverse outcome matter remote litigation relate bictegravir viiv healthcare company vhc file lawsuit district court delaware allege commercialization bictegravir sell commercially combination tenofovir alafenamide emtricitabine biktarvy infringe vhcs patent patent cover vhcs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent lawsuit vhc seek billion dollar allege damage comprise vhcs lose profit royalty sale bictegravir launch trial addition court find liable infringement expect vhc seek royalty sale trial vhc file lawsuit federal court canada allege activity relate bictegravir compound infringe vhcs canadian patent patent issue shionogi co ltd vhc patent compound patent covering vhcs dolutegravir believe bictegravir infringe claim patent november december vhc file lawsuit france germany ireland uk assert relevant national designation european patent australia assert australian patent japan assert japanese patent korea assert korean patent nos patent relate molecules vhc claim act integrase inhibitor believe bictegravir infringe valid claim vhcs patent prevail court proceeding date canada germany february gilead reach agreement settlement vhc viiv healthcare uk limited viiv healthcare uk limited shionogi co ltd glaxosmithkline mercury limited collectively viiv global resolution pende potential claim relate gilead sale biktarvy include litigation pende district court delaware jurisdiction outside united states describe february lawsuit pende united states dismiss lawsuit canada france ireland uk australia japan korea pursuant term settlement viiv grant gilead broad worldwide license covenant sue relate past present future development commercialization bictegravir connection settlement gilead onetime payment viiv billion quarter provide viiv ongoing royalty rate future sale biktarvy bictegravir component bictegravircontaining product united states october connection settlement gilead record pretax charge billion cost good sell consolidated statement income fourth quarter litigation relate preexposure prophylaxis august file petition request inter parte review patent nos collectively hhs patent ptab hhs patent assign department health human service hhs purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir disoproxil fumarate tdf prior exposure host immunodeficiency retrovirus process commonly know preexposure prophylaxis prep november department justice file lawsuit district court delaware allege sale truvada descovy use prep infringe hhs patent february ptab decline institute petition inter part review hhs patent april file breach contract lawsuit federal government court federal claim allege violation material transfer agreement mta relate research underlie hhs patent clinical trial agreement cta centers disease control prevention relate prep research predict certainty ultimate outcome litigation matter believe federal government breach mtas cta truvada descovy infringe hhs patent hhs patent invalid prior art description truvada use prep postexposure prophylaxis physician patient claim method year hhs file application patent trial date lawsuit court federal claim set june trial date lawsuit district court delaware set litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product prior patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval start december receive letter lupin ltd apotex inc shilpa medicare ltd shilpa sunshine lake pharma co ltd sunshine lake laurus labs natco pharma ltd macleods pharma ltd hetero labs ltd cipla ltd collectively generic manufacturer indicate submit andas fda request permission market manufacture generic version certain tafcontaining product generic manufacturer seek market generic version odefsey descovy vemlidy generic manufacturer challenge validity patent list orange book associated taf file lawsuit generic manufacturer intend enforce defend intellectual property november reach agreement shilpa resolve lawsuit shilpa addition january reach agreement sunshine lake resolve lawsuit sunshine lake settlement agreement file federal trade commission department justice require law october receive letter lupin ltd lupin indicate submit anda fda request permission market manufacture generic version symtuza product commercialize janssen gilead share revenue november janssen product lp janssen file patent infringement lawsuit lupin coplaintiff district court delaware separately file additional lawsuit lupin assert infringement additional patent court european patent claim party file opposition epo request revocation grant european patent cover sofosbuvir expire epo uphold validity certain claim sofosbuvir patent appeal decision seek restore original claim original oppose party appeal request revocation appeal hearing originally schedule july cancel new date set epo party file opposition epo request revocation grant european patent relate sofosbuvir expire epo conduct oral hearing opposition uphold claim original oppose party appeal request revocation party file opposition epo request revocation grant european patent cover taf expire epo upheld validity claim taf patent party appeal decision appeal hearing hold march validity claim uphold party file opposition epo request revocation grant european patent relate taf hemifumarate expire epo upheld validity claim taf hemifumarate patent party appeal decision party file opposition epo request revocation grant european patent cover cobicistat expire epo upheld validity claim cobicistat patent party appeal decision appeal process year epo opposition proceeding confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf taf hemifumarate cobicistat eu substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant ema lose patent protection compound revenue result operation negatively impact year include succeed year exclusivity lose antitrust consumer protection bristolmyers squibb company bms johnson johnson inc name defendant class action lawsuit file related drug treat hiv include drug combination antiretroviral therapy plaintiff allege defendant engage conduct restrain competition violation federal state antitrust law state consumer protection law lawsuit consolidate pende district court northern district california lawsuit seek bring claim behalf nationwide classesone direct purchaser consist largely wholesaler indirect endpayor purchaser include health insurer individual patient plaintiff seek damage permanent injunctive relief relief fall plaintiff file separate lawsuit effectively opt class action case assert claim substantively putative class case coordinate class action trial set march september generic manufacturers cipla ltd cipla usa inc cipla name defendant class action lawsuit file district court northern district california jacksonville police officer fire fighter health insurance trust jacksonville trust behalf endpayor purchaser jacksonville trust claim settlement agreement cipla settle patent dispute relate patent cover emtriva truvada atripla product permit generic entry prior patent expiry violate certain federal state antitrust consumer protection law plaintiff seek damage permanent injunctive relief relief february bms teva pharmaceutical industries ltd name defendant lawsuit file judicial district court state new mexico county santa fe new mexico attorney general new mexico attorney general allege defendant restrain competition violation new mexico antitrust consumer protection law new mexico attorney general seek damage relief believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage subject permanent injunctive relief award favor plaintiff product liability name defendant class action lawsuit product liability lawsuit relate viread truvada atripla complera stribild plaintiff allege viread truvada atripla complera andor stribild cause experience kidney bone andor tooth injury lawsuit pende state federal court california delaware maryland missouri new jersey involve plaintiff plaintiff case seek damage relief ground allege personal injury economic loss intend vigorously defend action believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage government investigation receive subpoena attorney office southern district new york request document relate promotional speaker program hiv cooperate inquiry qui tam litigation sale employee file qui tam lawsuit gilead march district court eastern district pennsylvania follow government decision intervene suit case unseal december lawsuit allege certain gilead hcv sale marketing activity violate federal false claim act state false claim act relator seek available relief statute employee file qui tam lawsuit gilead april california state court follow california attorney general office decision intervene relator serve gilead complaint august complaint allege violation california false claim act cfca employment law claim relator seek available relief cfca december gilead relator execute settlement agreement resolve lawsuit february court issue order dismiss lawsuit prejudice settlement material impact consolidate financial statement health choice advocate llc health choice file qui tam lawsuit gilead april new jersey state court follow new jersey attorney general office decision intervene suit health choice serve original complaint august lawsuit allege gilead violate new jersey false claim act clinical educator program sovaldi harvoni hcv hiv patient access program lawsuit seek available relief new jersey false claim act april trial court grant motion dismiss prejudice health choice appeal trial court dismissal health choice file qui tam lawsuit gilead make similar allegation texas state court follow texas attorney general office decision intervene suit health choice serve original complaint october lawsuit allege gilead violate texas medicare fraud prevention act tmfpa clinical educator program sovaldi harvoni hcv hiv patient access program lawsuit seek available relief tmfpa september texas court appeal sixth court appeal district grant request stay texas litigation case stay pende final judgment eastern district pennsylvania lawsuit file march discuss intend vigorously defend action believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage security litigation immunomedic officer director name defendant putative class action file consolidated september plaintiff file consolidated complaint november amend complaint july plaintiffs allege immunomedics individual defendant violate federal security law connection immunomedic biologic license application trodelvy seek certification class shareholder damage relief consolidated lawsuit pende district court district new jersey believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment relate inventory december commitment year approximately billion million million million million stockholder equity stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction december remain authorize repurchase program billion follow table summarize stock repurchase program year end december millions share amount share repurchase retire average price share addition repurchase program program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation share exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital base estimate average sale price issue share excess amount charge retain earning dividend follow table summarize cash dividend declare common stock million share amount dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performance share award unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change aoci component net tax unrealize gain unrealize gain foreign currency loss available loss cash translation net forsale debt flow hedge net million tax security net tax tax total balance december net unrealize gain reclassification net income net current period comprehensive income loss balance december net unrealize gain loss reclassification net income net current period comprehensive income loss balance december net unrealize gain loss reclassification net income net current period comprehensive income loss balance december amount reclassify net income gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify net income gain loss availableforsale debt security record income expense net consolidated statement income income tax impact allocate component comprehensive income material period present employee benefit equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan authorize issuance total million share common stock seven acquisition assume seven inc equity incentive plan subsequently amend restate gilead sciences inc equity incentive plan amend restate plan aggregate share issue plan assumption date exceed million share immunomedics acquisition assume immunomedics amend restate longterm incentive plan immunomedic plan refer plan plan plan subsequently merge plan aggregate share issue immunomedics plan assumption date exceed million share note acquisition additional information settlement stock award plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance share award employee director consultant december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option stock option grant january nonqualified stock option employee stock option generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage aggregate average remain intrinsic share exercise price contractual term value million dollar year million outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million million respectively weightedaverage grant date fair value stock option grant share share share respectively december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year restrict stock performance share award grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus sharebase awards entitle holder receive freely tradable share common stock vest rsus generally vest year date grant fair value rsu equal closing price common stock grant date grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize rsu psu activity relate information rsus psus weighted weight average average grant date fair grant date fair million share amount share value share share value share outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grant date performance objective define weightedaverage grant date fair value rsus grant share share share respectively weightedaverage grant date fair value psus grant share share share respectively total grant date fair value vest rsus psus million million million respectively total fair value respective vest date million million million respectively december million unrecognized compensation cost relate unvested rsus psus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer sixmonth lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december stockbase compensation follow table summarize total stockbased compensation expense include consolidated statement income year end december million cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax pretax stockbase compensation expense year end december billion include million noncash stockbase expense million million accelerate postacquisition stockbase expense relate acquisition immunomedic seven respectively note acquisition additional information income tax effect year end december include million income tax expense follow court appeal decision altera corp v commissioner require related party intercompany cost sharing arrangement share expense relate stockbased compensation stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience requisite service period shorter vest period employee retirement eligible valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million respectively maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million million december respectively net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock dilutive security outstanding period potentially dilutive share common stock result assume exercise outstanding stock option equivalent determine treasury stock method potential share common stock exclude computation dilute net income share attributable gilead common shareholder effect antidilutive million million million respectively follow table show calculation basic diluted net income share attributable gilead common stockholder year end december millions share amount net income attributable gilead share share calculation basic dilutive effect stock option equivalent share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder diluted income taxis income income taxis consist follow year end december million domestic foreign income income taxis income tax expense benefit consist follow year end december millions federal current deferred state current defer foreign current deferred income tax expense benefit income tax benefit include billion defer tax benefit relate intangible asset transfer foreign subsidiary ireland united states fourth quarter complete intraentity asset transfer certain intangible asset foreign subsidiary ireland transaction result stepup irish taxdeductible basis transfer asset accordingly create temporary difference tax basis exceed financial statement basis intangible asset result recognize defer tax asset billion consolidated financial statement expect able realize defer tax asset result intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material reconciliation federal statutory tax rate apply income income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit tax foreign earning foreignderive intangible income deduction defer tax intraentity transfer intangible asset settlement tax examination acquire iprd relate charge change valuation allowance nontaxable unrealized gain loss investment effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow december millions defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible excess tax basis book basis intangible asset upfront milestone payment research credit carryforward equity investment liability relate future royalty net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability property plant equipment excess book basis tax basis intangible asset total defer tax liability net defer tax asset liability valuation allowance million million december respectively increase valuation allowance primarily relate california research development tax credit valuation allowance million million december respectively increase valuation allowance primarily relate acquire attribute relate seven immunomedics acquisition capital loss relate equity method investment december federal net operating loss tax credit carryforward approximately million million respectively start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss state tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states foreign jurisdiction federal income tax purpose statute limitation open onwards onwards california income tax purpose certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination internal revenue service irish tax authority tax year differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total unrecognized tax benefit million billion december respectively recognize reduce effective tax rate period recognition interest penalty relate unrecognized tax benefit include income tax expense million income tax benefit million income tax expense million consolidate statement income year end december respectively accrue interest penalty relate unrecognized tax benefit million million december respectively december believe reasonably possible unrecognized tax benefit decrease approximately million month potential settlement tax authority follow rollforward total gross unrecognized tax benefit year end december million balance begin period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period connection tax cut job act record federal income tax payable transition tax mandatory deem repatriation foreign earning payable eightyear period december accrue billion billion respectively transition tax amount accrue december approximately million expect pay year item change disagreement accountant account financial disclosure applicable report independent register public accounting firm stockholder board director gilead sciences inc opinion internal control financial reporting audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion gilead sciences inc company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidate balance sheet company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp san jose california february item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae de securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af df exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable item c disclosure foreign jurisdiction prevent inspection applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading gilead board director nominees board structure executive officer applicable delinquent section report write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website wwwgileadcom investors section corporate governance intend disclose future amendment certain provision code ethic waivers code ethic grant executive officer director website business day follow date amendment waiver item executive compensation information require item incorporate reference section proxy statement headings executive compensation committee board director compensation talent committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference item annual report head equity compensation plan information section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction director independence information require item incorporate reference section proxy statement headings gilead board director board process item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item